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The advances in nanotechnology and medicine are opening doors to new diagnostic and 
therapeutic possibilities, which are not accessible with the current approaches. However, the 
discovery of new therapeutic agents also requires the development of innovative drug delivery 
strategies. In this context, the pulmonary route is proposed as a powerful entrance for innovative 
treatments. The respiratory system offers very favourable deatures that improve the delivery and 
pharmacokinetics of drugs intended for both local and systemic therapies. Apart from being a non-
invasive route, the alveolar clearance of drugs and nanoparticles is considerably slower than in 
other parts of the body due to low enzymatic activity. Additionally, a very large respiratory surface 
(<140 m2 approximately) and a thin alveolar epithelium, with high permeability and considerable 
vascularisation, are key factors to facilitate adsorption and targeting of drugs. However, during its 
evolution, the lung has developed several barriers to prevent the access of undesirable entities. 
Therefore, it is essential to investigate how to overcome them and evaluate the paradoxical 
possibility of using them for drug entry. In this sense, pulmonary surfactant, which has been poorly 
considered in pulmonary drug delivery research, is named to become a powerful tool to vehiculize 
novel therapeutics agents. 
Pulmonary surfactant is an essential membrane-based lipid-protein material synthetized and 
secreted to the alveolar region by type-II pneumocytes in the form of multilamellar structures. It 
coats the respiratory surface and is in charge of preventing alveolar collapse while minimizing the 
necessary work during breathing. Throughout respiration, the alveoli are continuously dilating and 
contracting, forcing pulmonary surfactant to adapt to such highly dynamic environment. Its 
sophisticated composition, including 90% lipids and 10% hydrophilic (SP-A and -D) and highly-
hydrophobic (SP-B and -C) proteins, allows pulmonary surfactant for efficiently adsorbing and 
travelling over the respiratory air-liquid interface. Once there, the compression that occurs upon 
exhalation forces the interfacial films to fold, forming a three-dimensional network of 
interconnected membranes with unique mechanical properties, and excluding certain lipids, 
lipid/protein complexes and any other non-compressible molecules from the interface. As a 
consequence, during the expansion (upon inhalation) free-surfactant regions could be generated, 
favouring the spreading of pulmonary surfactant towards the alveoli following the Marangoni 
Effect, and also the adsorption of new pulmonary surfactant coming from type-II pneumocytes. 
Therefore, these phenomena could facilitate not only the interfacial trip of pulmonary surfactant 
and the transport of therapeutics over the respiratory surface, but also their release in the 
perialveolar region during the process of breathing. 
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Levering the exceptional interfacial properties of pulmonary surfactant, the main objective 
of this Thesis is to explore the potential of this surface-active system to vehiculize different drugs 
through the airways and set the basis of a novel and less-invasive strategy, the interfacial therapy. 
In order to accomplish this objective the following specific aims are proposed: 
1. Stablish and optimize different strategies to combine several molecules of medical interest 
with clinical and synthetic pulmonary surfactants.  
2. Evaluate the possible detrimental effects of the vehiculized molecules on the interfacial 
behaviour of pulmonary surfactant. 
3. Verify the vehiculizing potential of different surfactant formulations through in vitro air-
liquid interfaces. 
4. Determine the implications of compression-expansion breathing dynamics on this novel 
drug delivery strategy. 
5. Confirm the feasibility of the interfacial therapy in vivo, determining the main factors 
implicated and testing its potential synergistic therapeutic effects. 
The present Thesis has explored the vehiculizing capabilities of pulmonary surfactant in vitro 
and in vivo. Combining different biophysical techniques with fluorescence spectroscopy or 
fluorescence and atomic force microscopy (AFM), the feasibility of this new drug delivery strategy 
has been firstly evaluated in vitro.  The Captive Bubble Surfactometer, which emulates the 
interfacial mechanics of the alveolus, has been used to evaluate the functionality of surfactant/drug 
mixtures. Langmuir-Blodgett techniques permits the structural characterisation of surfactant and 
surfactant/drug films. With interfacially-connected Whilhelmy and Langmuir-Blodgett troughs, an 
in vitro model of the respiratory air-liquid interface has been designed and optimised to perform 
different vehiculization assays. It has been evaluated how pulmonary surfactant behaves and 
travels along the interface, what happens if it shares the trip with different drugs, and whether the 
vehiculized entities are excluded from the interfase under compression-expansion cycling. The 
results demonstrated that different drugs (corticosteroids and tacrolimus) can be incorporated 
without affecting the functionality of pulmonary surfactant, while it is capable of vehiculizing them 
along the air-liquid interface. Additionally, breathing-like compression-expansion cycling favours 
the interfacial trip of surfactant-containing drugs, enhances adsorption of new material and 
facilitates drug release processes. 
Although the biophysical models provide a robust understanding of elementary processes 
involved in the interfacial pulmonary drug delivery, to transfer properly the generated knowledge 
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to clinics further experiments are required to take into account the native context that the desired 
therapy will encounter in the lungs. Therefore, this Thesis has also addressed the pulmonary 
surfactant-promoted drug delivery approached directly on real lungs using in vivo model systems. 
The distribution, synergistic anti-inflammatory effects and the cells that internalised the drug  
tacrolimus have been evaluated in LPS-induced murine models of Acute Lung Injury (ALI). The 
experiments confirmed that the combined therapy with tacrolimus and porcine-derived exogenous 
surfactant had considerably better anti-inflammatory effects, preventing the pulmonary oedema 
and reducing the infiltration of inflammatory cells into the alveolar spaces. Additionally, the 
presence of pulmonary surfactant enhanced the internalization of tacrolimus into macrophages at 
the alveolar spaces. 
Hence, this Thesis has established for the first time the basis of a new and non-invasive 
strategy targeting the lungs and likely peripheral locations. Clinical and synthetic surfactants could 
be the basis of ideal materials to vehiculize different therapeutics (i.e. anti-inflammatory or 
antibiotic drugs, antibodies, etc.) over the respiratory surface and help them to reach deeper 
regions in the lung, including the alveoli, where playing a better and more efficient therapeutic 
activity. 
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Uno de los retos de los últimos años ha sido diseñar y desarrollar nuevas estrategias para 
el transporte de fármacos, particularmente estrategias menos invasivas y dirigidas a dianas 
específicas del organismo. En este sentido, los nuevos avances en nanotecnología y biomedicina 
están abriendo nuevas posibilidades terapéuticas y de diagnóstico. Una de las vías con mayor 
potencial para la administración de fármacos, tanto para tratamientos locales como periféricos, es 
a través de las vías aéreas, especialmente para compuestos con baja solubilidad en medios 
acuosos y con escasa biodisponibilidad cuando se administran por vías convencionales (oral o 
tópica). Las ventajas más evidentes que presenta el sistema respiratorio frente a otras vías de 
administración son su gran superficie (100 m2 aprox.), el fino epitelio alveolar que lo recubre, la 
permeabilidad de sus membranas y su alta vascularización (5 L/min aprox.), que permiten una 
elevada y rápida absorción de moléculas. Además, la degradación de fármacos en los pulmones 
es lenta, debido a la baja actividad enzimática intra y extracelular. Sin embargo, durante su 
evolución el sistema respiratorio ha desarrollado diversas barreras para evitar el acceso de 
sustancias y microorganismos nocivos. Por tanto, resulta esencial investigar cómo sobrepasarlas 
y evaluar la posibilidad paradójica de usarlas para transportar fármacos. En esta línea, el 
surfactante pulmonar, que no ha sido tenido en cuenta en la mayoría de los estudios de transporte 
de fármacos, se propone como una herramienta eficaz para vehiculizar una nueva generación de 
agentes terapéuticos. 
El surfactante pulmonar es un material formado por membranas de lípidos y proteínas 
sintetizado y secretado al espacio alveolar por los neumocitos tipo II en forma de estructuras 
multilamelares. Cubre toda la superficie respiratoria y está encargado de prevenir el colapso 
alveolar minimizando el trabajo necesario durante el proceso de respiración. Durante este 
proceso, los alveolos está continuamente dilatándose y contrayéndose, forzando al surfactante 
pulmonar a adaptarse a estas condiciones tan dinámicas. Su sofisticada composición, 90% lípidos 
y 10% proteínas hidrofílicas (SP-A y SP-D) e hidrofóbicas (SP-B y SP-C), permite al surfactante 
adsorberse eficientemente la interfase que se forma entre la fina capa de agua que recubre toda 
la superficie respiratoria y el aire que respiramos, y viajar rápidamente a lo largo de ella. Una vez 
en la interfase, la compresión originada durante la exhalación fuerza a la película interfacial de 
surfactante a plegarse, formando una red de estructuras tridimensionales interconectadas con 
propiedades biofísicas únicas. Estas estructuras están enriquecidas en todos aquellos 
componentes del surfactante que, incapaces de soportar elevadas presiones superficiales, 
favorecen la exclusión de complejos lípido-proteicos y de cualquier otro compuesto poco 
compresible. Como consecuencia, durante la expansión de la interfase (inhalación) se podrían 
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generar espacios libres de surfactante, que favorecen la difusión interfacial hacia los alveolos, 
atendiendo al efecto Marangoni, y la adsorción de nuevo surfactante proveniente de los 
neumocitos tipo II. Esto podría facilitar no solo el viaje interfacial del surfactante pulmonar y el 
transporte de fármacos a lo largo de la superficie respiratoria, sino también la liberación de 
fármaco durante el proceso de reparación. 
Aprovechando las características únicas del surfactante pulmonar, el objetivo principal de 
esta Tesis es explorar el potencial de este sistema para vehiculizar diferentes agentes terapéuticos 
a través de las vías aéreas y establecer las bases de una nueva estrategia terapéutica menos 
invasiva, la terapia interfacial. Para ello se plantean los siguientes objetivos específicos: 
1. Establecer y optimizar diferentes estrategias para combinar diferentes moléculas de 
interés médico con surfactantes clínicos y sintéticos. 
2. Evaluar los posibles efectos deletéreos de las moléculas vehiculizadas en el 
comportamiento interfacial de surfactante pulmonar. 
3. Verificar el potencial vehiculizador de diferentes formulaciones de surfactante a través de 
modelos de interfases aire-líquido in vitro. 
4. Determinar las implicaciones de la dinámica respiratoria en esta nueva estrategia 
terapéutica. 
5. Confirmar la viabilidad de la terapia interfacial en modelos in vivo, determinando los  
principales factores implicados y analizando su potencial efecto sinérgico. 
En la presente Tesis Doctoral se han explorado las capacidades vehiculizadoras del 
surfactante pulmonar in vitro e in vivo. Combinando diferentes técnicas biofísicas con 
espectroscopía de fluorescencia o microscopía de fluorescencia o de fuerzas atómicas (AFM), se 
ha evaluado por primera vez in vitro la viabilidad de esta nueva estrategia de vehiculización. El 
Surfactómetro de Burbuja Cautiva (CBS), que emula la mecánica de compresión-expansión 
alveolar, se utilizó para evaluar la funcionalidad interfacial de las mezclas surfactante/fármaco. Las 
técnicas de Langmuir-Blodgett se usaron para la caracterización estructural de las películas de 
surfactante y el efecto que los fármacos podrían tener sobre ellas. Con balanzas de Wilhelmy y 
Langmuir-Blodgett conectadas entre sí por puentes interfaciales se ha recreado una superficie 
respiratoria in vitro para realizar diferentes experimentos de vehiculización. Con estos nuevos 
modelos biofísicos, se ha podido evaluar cómo se comporta y cómo viaja el surfactante pulmonar 
a lo largo de la interfase aire-líquido, qué pasa si comparte el viaje interfacial con otros pasajeros 
y si éstos son excluidos de la interfase durante los ciclos de compresión y expansión. Los 
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resultados obtenidos demostraron que diferentes fármacos (corticosteroides y tacrolimus) 
pueden ser incorporados y transportados en los complejos del surfactante sin alterar sus 
propiedades interfaciales. Además, los ciclos de compresión y expansión favorecen el viaje 
interfacial y la vehiculización, promueven la adsorción de nuevo material y facilitan la liberación 
del fármaco de la interfase. 
Aunque los modelos biofísicos aportan un conocimiento amplio de los procesos elementales 
implicados en el transporte interfacial de fármacos, para poder transferir adecuadamente este 
conocimiento a la clínica, es necesario realizar experimentos adicionales teniendo en cuanta el 
contexto nativo que las moléculas de interés encontrarán en los pulmones. Por tanto, en esta 
Tesis también se han llevado a cabo experimentos en sistemas in vivo. Utilizando modelos de ALI 
(del inglés, Acute Lung Injury) inducido por LPS, se ha evaluado la distribución y efectos 
antinflamatorios sinérgicos, así como el tipo de células que son capaces de internalizar el 
tacrolimus. Los experimentos confirmaron que la terapia combinada de surfactante con tacrolimus 
mejoraba enormemente los efectos antinflamatorios del fármaco, previniendo el edema pulmonar 
y reduciendo la infiltración de células proinflamatorias en los espacios alveolares. Además, la 
presencia de surfactante pulmonar promovía la internalización de tacrolimus por macrófagos en 
el espacio alveolar. 
En resumen, en esta Tesis Doctoral se han establecido por primera vez las bases de una 
estrategia de vehiculización de fármacos nueva y menos invasiva cuya diana puede ser no solo el 
sistema respiratorio, sino a través de éste, el resto del organismo. Los surfactantes clínicos 
actuales u otros sintetizados ad hoc podrían ser la base de nuevos adyuvantes ideales para 
vehiculizar diferentes agentes terapéuticos (por ejemplo fármacos antiinflamatorios, antibióticos, 
anticuerpos, etc.) a lo largo de la superficie respiratoria y ayudarlos a alcanzar regiones más 
profundas y distales del pulmón, incluyendo los alveolos, donde puedan ejercer una mejor y más 
eficiente actividad terapéutica. 
  
 
  
 
 
 
 
  
This introduction is based on two review articles: 
o Hidalgo, A.; Cruz, A.; Perez-Gil, J. Barrier or carrier? Pulmonary surfactant 
and drug delivery. Eur J Pharm Biopharm 2015, 95 (Pt A), 117-27. 
o Hidalgo, A.; Cruz, A.; Perez-Gil, J. Pulmonary surfactant and nanocarriers: 
Toxicity versus combined nanomedical applications. Biochimica et 
biophysica acta 2017, 1859 (9 Pt B), 1740-1748. 
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The applications of nanotechnology are diverse. Particularly, in biomedicine and healthcare, 
nanotechnology has the potential to advance from current general treatments to safer, more 
personalised, precise, and patient-friendly therapies. Nanotechnology is creating great 
expectations in diagnosis, drug delivery and targeted actions. Since Richard Feynman, Physics 
Nobel Prize awardee in 1965, seeded the first concepts of nanotechnology in his talk “There's 
Plenty of Room at the Bottom” at the California Institute of Technology in 1959 1, many 
researchers have focused on this promising nanoscale technology. As a consequence public and 
private global investment has increased not only to pursue the generation of knowledge but also 
its transference to society2. It is estimated that global nanomedicine market moved $134.4 billion 
in 2016 and $151.9 billion in 2017, and the total market for nanomedicine products is projected 
to grow and reach $293.1 billion by 20223. 
It is obvious that nanotechnology can contribute to develop new therapeutic strategies and 
improve the diagnosis and treatment of different diseases considerably. In particular, 
nanomedicines may reach the place of action with extreme precision, while triggering careful drug 
release. Furthermore, more than 90% of new drugs are classified as class II or IV, according to 
the Biopharmaceutical Classification System (BCS), meaning that they have low solubility in 
water4, 5. This creates the need to design new tools and strategies associated with development 
of novel therapies. 
In this context, the pulmonary route is called to become a powerful way of entry for 
innovative treatments. The respiratory system presents unique features that may facilitate the 
delivery and pharmacokinetics of drugs intended for both local and systemic therapies. 
Sophisticated devices for delivering inhaled drugs have been made available in recent times, but 
this route of drug administration has been known thousands of years ago as the basis of ancestral 
techniques, such as burning and inhaling aromatic and medicinal plants6, 7. It is a non-invasive 
route, with a slow clearance of drugs and nanoparticles due to low enzymatic activity. Thus, the 
pulmonary route often allows a reduction of drug dosage while still reaching a high local 
concentration8. Additionally, a very large respiratory surface (more than 140 m2 approximately), 
and a thin alveolar epithelium, with high permeability and considerable vascularisation are key 
factors to facilitate adsorption, targeting and rapid onset of action. As a result, dose and dosing 
frequency could be reduced, ultimately constituting an easier and more patient-friendly delivery 
route, especially the chronic lung diseases. However, during evolution, the respiratory system has 
developed several barriers to prevent the access of pathogens and undesirable and harmful 
compounds. These barriers pose a serious handicap for drug administration. Therefore, it is crucial 
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to investigate how to overcome these barriers and evaluate the paradoxical possibility of using 
them to design novel tools for drug entry. 
Historically considered a barrier against pathogens and harmful particles and essential for 
the process of breathing, pulmonary surfactant (PS) offers great opportunities to solve the 
solubility problem of hydrophobic drugs while reaching deep regions in the lungs. This PhD Thesis 
explores the potential use of pulmonary surfactant as a vehicle for delivering drugs stabilising vasic 
concepts to develop a new and non-invasive drug delivery strategy: the interfacial therapy. In this 
introduction, based on two already published review articles4, 9, the importance of vehiculizing 
therapies will be firstly explained, as well as the anatomy of the respiratory system and its relevant 
properties for drug entry. Then, it will describe what pulmonary surfactant is, how it works and 
the main actors during its synthesis and recycling. Finally, surfactant-related pathologies, current 
therapeutic surfactants and key aspects that should be considered when using pulmonary 
surfactant as a carrier will be deeply discussed. 
Why should we vectorize drugs? 
When drugs enter the body, they must overcome different barriers until reaching the target 
location. Therefore, diverse strategies need to be developed to facilitate the entrance of 
therapeutic agents, while extending their retention time and optimizing the release of the drug. 
Novel formulations have been developed through the generation of insoluble complexes that 
cluster the drug in nanometer-size defined particles. This approach has been explored to 
administer corticosteroids, sex hormones, insulin, siRNA, anti-bodies or even stem cells. Many 
other structures and sophisticated micro- and nano-vehicles have been studied for more than 30 
years to address a so-called ‘smart’ vehiculization. Drug vehiculization, vectorization or 
encapsulation principally look for: (i) protecting drugs from degradation, (ii) increasing adsorption 
and cellular penetration rates, (iii) controlling drug distribution to increase efficacy and decrease 
side-effects, and (iv) improving diagnostic imaging techniques. Furthermore, vehicles could be 
functionalised to: (a) increase their biological half-life (e.g. coating with PEG), (b) target defined 
locations in the body with specific ligands, (c) allow drug release under particular physiological or 
pathological conditions (in response to changes in pH, temperature, etc.), (d) avoid or make use 
of lysosomal degradation once the carrier enters into the cell, and/or (e) engineer multifunctional 
nanosystems10. In general, every nanocarrier that enters in the body should be biocompatible, 
biodegradable and possess high drug uploading capacity11. 
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Several approaches developed according to those principles are currently at preclinical and 
clinical trials, such as polymeric carriers, lipid nanosystems or dendrimers. Nevertheless, as 
important as the vehicles are the ‘motorways’. One of the challenges in the last years has been 
to develop non-invasive and patient-friendly drug delivery strategies which could allow reducing 
dosages and secondary effects while targeting specific locations in the body. In this sense, the 
respiratory system is proposed as a perfect way of entry and has been increasingly considered in 
the design and development of new drug delivery strategies. The particular features of the 
respiratory surface and the presence of pulmonary surfactant, together with lung physiology, make 
the respiratory system a good choice when looking for a powerful and non-invasive way of 
delivering for different therapies. 
Dissecting the anatomy and physiology to understand pulmonary 
drug delivery 
The respiratory system is specialized in capturing O2 from the environment and clearing CO2 
produced by cellular metabolism. In terrestrial animals, adult amphibians and lungfishes, this 
phenomenon is carried out by very complex structures adapted to take oxygen from air, the lungs. 
In addition to the breathing process, the lung establishes a first barrier protecting the respiratory 
system from the entrance of external noxious agents such as particles and different potentially 
pathogenic microorganisms. It is therefore necessary to properly understand the functions, 
anatomy and physiology of the respiratory system when considering pulmonary drug delivery. 
In mammals, the lung is a branching organ composed by tubes that progressively subdivide 
from conducting to respiratory regions, reaching a total surface of more than 140m2 (see Figure 
1) The former includes the nasal cavity, nasopharynx, trachea, bronchi and terminal bronchioles, 
whose main function is to move air into and out of the lung. The respiratory area, on the other 
hand, includes respiratory bronchioles and air sacs or alveoli, which are involved in gas exchange 
between the atmosphere and the bloodstream. In humans, air flows efficiently along their 23 
tubular bifurcations from the trachea to alveoli, decreasing in diameter (up to 200 µm approx.) 
and wall thickness (until 0.1-0.4 µm approx. in alveoli)12. Continuously exposed to the 
environment and, therefore, to potentially harmful compounds and microorganisms, the 
respiratory system has developed a very sophisticated multi-layered barrier consisting of several 
structured levels and innate defensive agents. 
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Figure 1: Diagram of pulmonary airways. Representation of the 23 bifurcations that occurs from trachea to 
alveoli. Notice that the conductive zone contains 16 bifurcations, while the respiratory area 5 (from the 17th to 
23rd) 12. 
When exogenous entities enter the respiratory system, the first layer that they encounter is 
the mucus and an aqueous hypophase in the conductive regions, lining ciliated and club cells13. 
This first layer mostly traps and clears foreign bodies to prevent their progression to the respiratory 
region, the alveolar spaces. If avoiding the first line of defence, the respiratory area contains 
additional layers to restrain them. It is limited by a very thin cell monolayer of type I and II 
pneumocytes14. The former transports ions and proteins, and is in charge of the gas exchange, 
while the latter synthesises the pulmonary surfactant (PS) complex. This cell monolayer is covered 
by a thin aqueous film where alveolar macrophages (AMϕ) can be found. On top of this aqueous 
layer is where pulmonary surfactant carries out its physiological function15. The whole defence 
system at the respiratory spaces therefore includes mucus and the mucociliary escalator at the 
upper airways, and PS with its integrated defence collectin proteins and macrophages (Mϕ) at 
the distal alveolar spaces. Other defensins and antibiotic molecules are secreted into the aqueous 
layer coating the whole lung to aid maintaining sterility16, 17. Under the epithelium, there is an 
interstitial layer with endothelial cells forming the blood and lymphatic capillaries. The tight 
junctions sealing the layers of pulmonary cells and endothelium complete the defence system of 
the respiratory surface. 
In addition to these barriers, which also oppose to the entrance of therapeutic agents, there 
is also a steric hindrance as a consequence of lung geometry. Progressive slimming of wall 
thickness facilitates gas exchange, the local action of drugs and their potential entrance into the 
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bloodstream, but unfortunately leaves the body exposed to potentially deleterious agents. 
However, the gradual reduction of the diameter of pulmonary ducts contributes to prevent their 
entrance to deep lung regions. The delivery of drugs and nanocarriers targeted to the deepest 
regions also have to deal with this limitation. Therefore, understanding the processes by which 
different bodies are retained and deposited into different regions of the lungs could help to 
optimise drug delivery approaches. 
An ancient entrance for novel therapeutic strategies 
The respiratory system has been considered as an accessible drug delivery route for 
thousands of years, when our ancestors burned and inhaled aromatic and medicinal plants to treat 
problems in the body, relieve the pain caused by injuries, or stimulate the nervous system. The 
lung provides a non-invasive route and it possesses large surface area, thin alveolar epithelium, 
high permeability and considerable vascularisation. Nowadays, the inhalation pathway is being 
considered by an increasing number of therapeutic approaches, both for local and systemic 
targets18. For example, delivering peptidic drugs has been systematically explored using inhalable 
formulations as an alternative to the non-feasible oral administration19. Administration of inhaled 
insulin, for instance, has been object of intense research and investment with still non-acceptable 
results, a probable consequence of inefficient strategies to overcome pulmonary barriers in a 
predictable and quantitative way. 
There are many variables that condition the fate of any particle or microorganism entering 
the airways. As mentioned above, the anatomy of the lung plays an important role. But there are 
other factors that also affect deposition in lungs, such us the ventilation parameters (breath 
pattern, flow rates and tidal volume), the place where particles are initially deposited, as well as 
the physiological or pathological scenarios. In addition to the intrinsic factors of the respiratory 
context, the particle properties (shape, size, density and surface) are also fundamental4, 20, 21. In 
order to properly classify nanoparticles, in drug delivery the aerodynamic rather than the geometric 
diameter is extensively used. The former considers size, density and shape of particles as a body, 
instead of only size, as the latter (e.g. a large porous sphere may have a small aerodynamic 
diameter but a large geometric diameter)4. 
More than 80% of submicron-size particles are exhaled or expectorated together with the 
mucus. The rest can be deposited following three main phenomena: inertial impaction, 
gravitational sedimentation and diffusion4, 22, 23, 24. Particles as of 5µm, such us pollen, fungal 
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spores or fog, settle in the upper airways by inertial impaction. Bodies between 0.4µm and 5µm, 
like bacteria, the biggest automobile-emitted particles and smog, are usually deposited on the 
respiratory surface by sedimentation. In the case of viruses, tobacco smoke, smaller automobile-
emitted particles or nanoparticles smaller than 0.5µm, they normally reach the alveolar region by 
diffusion, a Brownian-motion-based phenomenon22, 25. The shape, size, density and surface of 
vehicles should therefore be optimized to efficiently reach the desirable location, to get either local 
or peripheral action. When the effect is intended to be local, the target will depend on the place 
where the pain, pathogen or injury are located. However, if the treatment is targeted beyond the 
lung to other organs, it should reach a region where the surface area, permeability and 
vascularization is high enough. The upper airways only constitute 5% of the respiratory surface, 
vascularity is low and clearance by mucus and ciliated cells is highly active26. However, the alveolar 
region possesses 95% of the area, there are plenty of lymphatic and blood capillaries and the 
trans-epithelial transport is favoured by its thin membranes. A proper combination of drugs and 
properly designed nanocarriers with pulmonary surfactant could enhance vehiculation over the 
respiratory surface to alveoli, not only with the purpose of optimizing distribution but also to 
prevent clearance, which could reduce dosage, side effects and considerably improve efficacy. 
Pulmonary surfactant: A promising approach for transporting drugs 
Since Kurt von Neergaard suggested in 1929 the existence of a surface active material in 
the lungs, several studies have been carried out in order to describe its composition, structure 
and function, as well as the disorders related with its dysfunction or deficiency 27. However, it was 
not until 25 years later when the Briton Richard Pattle and the American John Clemens 
concurrently confirmed the existence of the pulmonary surfactant system 27. The main function of 
this material is to reduce surface tension at the air-liquid respiratory interface down to values 
below 2mN/m, preventing pulmonary collapse during expiration and minimizing the work required 
to open the lungs during inspiration 28. Additionally, this material also plays a role in defence, 
acting as a barrier against pathogens and undesirable elements, serves to maintain the fluid 
balance across the alveolar-capillary barrier and transports mucus and inhaled particles hindering 
their adhesion within the upper airways29. 
The absence or disruption of this material impedes the normal breathing cycle. At the first 
contact of the lungs with the breathing air, alveoli would collapse leading unavoidably to death. 
Consequently, different surfactants formulations, typically obtained from animal sources, have 
been developed to take care of preterm neonates, where this essential system has not properly 
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matured yet. Apart from surfactant replacement therapies (SRTs), new surfactant-based 
therapeutic advances are currently under study, such as new procedures of PS administration 
(e.g. aerosolization or nebulisation) or its use as a drug delivery system29, 30.  
Due to its unique biophysical properties, which will be further explained below, pulmonary 
surfactant has the capability to adsorb very rapidly (within seconds) into the lung air-liquid 
interface and, once there, to spread efficiently over it. Since it is mainly composed by lipids, it 
offers a perfect hydrophobic environment to solubilise different poorly water-soluble molecules. 
Conversely, PS is not an effective agent to retain hydrophilic substances because of intrinsically 
dynamic and permeable character30, 31, 32, 33. Consequently, it is important to combine PS with 
carriers that could retain not only hydrophobic, but also hydrophilic molecules, whilst they interact 
and travel associated to PS. In order to better understand the therapeutic possibilities of PS per 
se and as a drug delivery system, it is necessary to firstly revise what pulmonary surfactant is and 
how it works in the lungs. 
A general view of pulmonary surfactant composition, structure and function 
Pulmonary surfactant is a lipid-protein surface-active material that coats the whole 
respiratory surface in mammals. It is synthetized by type II pneumocytes and secreted in the form 
of multilamellar structures into the alveolar spaces28. It is composed of approximately 90% lipids 
and 10% proteins34, 35 (see). Although the lipid composition varies between different species36, 37, 
38 and according to environmental39, physiological40 or pathological41 conditions, it is mainly made 
up of phospholipids, with the saturated species dipalmitoylphosphatidylcoline (DPPC) 
representing around 40% by mass30. Due to its saturated acyl chains, DPPC can reach a highly 
lateral packed state during compression of alveolar interface, which makes it the key responsible 
for the surface tension reduction capabilities of surfactant. Apart from DPPC, PS contains other 
unsaturated phosphatidylcholines (25%) and the anionic phosphatidylglycerol (8%). Additional 
lipids are phosphatidylethanolamine (5%), phosphatidylinositol (3%), phosphatidylserine and 
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sphingomyelin, as well as neutral lipids, being cholesterol the most abundant (8-10%)34, 42.
 
Figure 2: Pulmonary surfactant composition. DPPC: dipalmitoylphosphatidylcholine; PC: phosphatidylcholine; 
PG: phosphatidylglycerol; PE: phosphatidylethanolamine; PI: phosphatidylinositol; SP: surfactant protein 
(elaborated with data from 30). 
Although proteins constitute the smallest percentage by mass in PS, they are crucial for its 
function. There are four specific surfactant proteins known so far, which can be classified into two 
different groups: the hydrophobic proteins SP-B and SP-C34, and the hydrophilic proteins SP-A 
and SP-D. The formers contribute to mechanical stability of the interfacial films and are directly 
involved in interfacial adsorption of surface active molecules into the air-liquid interface. It has 
been demonstrated that deficiencies or lack of surfactant proteins produce severe dysfunctions in 
the respiratory process. Of particular importance is the lack of total SP-B, which leads to death 
shortly after birth30. The hydrophilic proteins, on the other hand, belong to the C-type lectin 
superfamily of collectins, whose main functions are related to surfactant homeostasis and the 
innate host defence, facilitating the recognition, binding, and clearance of pathogens from the 
lung43. SP-A and SP-D also exhibits anti-inflammatory effects, through inhibition of the activation 
of the complement system, and blocking of the binding of Toll-like receptor (TLR) ligands to 
TLR2, TLR4 and TLR co-receptors MD2 and CD14 in alveolar macrophages43, 44, 45, 46. 
The different components of pulmonary surfactant are assembled and stored as tightly 
packed membranes in lamellar bodies (LB) in type-II pneumocytes. These structures have a 
spherical shape with 1-3µm size and contain multiple concentrically organized membranes47, 48. 
SP-B and the ATP-binding cassette transporter A3 (ABCA3) seem to play an essential role for 
their biogenesis28; ABCA3 would translocate phospholipids at the inner membrane, while SP-B 
oligomers could form allowing PLs distribution. After contacting and fusing with the plasma 
membrane, LBs are secreted into the water-lining alveolar subphase. Subsequently, different 
structures are generated as a consequence of changes in pH, hydration and calcium concentration, 
finally creating a surface membrane network28, 47, 49. Particularly remarkable is the reorganization 
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of a fair portion of these membranous structures into the so-called tubular myelin (TM), directly 
formed from LBs and containing numerous square-shaped tubular membrane arrays organised in 
a net-like structure apparently stabilised by SP-A47, 50, 51 (see Figure 3). This structure has not 
shown a clear implication in reducing surface tension52, and it has been speculated that could 
possesses an antimicrobial role53, 54, acting as a sticky three-dimensional net trapping microbes 
and undesirable matter. 
 
Figure 3: Electron micrograph section of rat lung showing lamellar bodies (LB) and tubular myelin (TM). A: At 
the bottom of the micrograph a type II pneumocyte with a LB can be appreciated. Also secreted LB (small arrow) 
and TM (large arrows) are shown 55. B: LB and TM secreted into the subphase (bar = 1µm). At lower left it is 
detailed the TM structure (bar = 0.1µm) 35. 
Regarding SP-B and SP-C, both enable the adsorption of new surface active molecules from 
this network into the air-liquid interface. Once there, PS components form very rapidly a layer that 
diffuses laterally through the interface28. This membrane network of interconnected membranes 
seems to facilitate the incorporation of new material28 and O2 diffusion from the alveolar air spaces 
into the inner alveolar layers56. In an analogous fashion, surfactant could also facilitate the 
spreading of therapeutic molecules over the respiratory surface to reach the alveolar region. 
How pulmonary surfactant works at the respiratory air-liquid interface 
Water molecules in the bulk phase attract and interact one to another in all directions, mainly 
through hydrogen bonds and dipole-dipole interactions. When molecules of water are exposed to 
air, the attractive interactions unbalance and water tends to minimize the surface area in contact 
with the airspace, maintaining a constant volume. The force that withstand surface expansion is 
known as surface tension, which, in the case of water at 37°C is around 70mN/m54. At the 
respiratory surface, lined by a layer of water, a hydrophobic-hydrophilic interface is generated. The 
Introduction 
 
29 
 
resulting surface tension would hinder the process of breathing, maximising the effort required to 
expand the alveoli (at inspiration). This is prevented by the presence of a surface active material 
into this interface, the pulmonary surfactant. Phospholipids, which are the main component of 
pulmonary surfactant, are amphipathic molecules able to interact with water and, at the same 
time, orientate their hydrophobic acyl chains to air. As a consequence, they replace interfacial 
water molecules in contact with air and reduce surface tension to very low values, depending on 
their interfacial density(see Figure 4). 
 
Figure 4: Role of phospholipids in the air-liquid interface. A: Schematic representation of the interfacial 
behaviour of phospholipids and reduction of surface tension (increase of surface pressure). B: Structure of a 
phospholipid.  
The alveoli, where pulmonary surfactant is most abundant, are continuously compressing 
and expanding, forcing the pulmonary surfactant film to adapt to such highly dynamic environment. 
Thus, surfactant must simultaneously exhibit three essential properties to work efficiently at the 
interface: (i) very rapid interfacial adsorption to replace used surfactant, (ii) proper compressibility 
to reach very low (<2 mN/m) surface tension at the endo of expiration and (iii) efficient re-
spreading capabilities when alveoli re-expand during inspiration57. The high lateral pressures (low 
tensions) reached during expiration, when the interfacial surfactant film is subjected to 
compression, produces the exclusion from the interface of those molecules that do not support 
extreme packing through a process known as squeeze-out (see Figure 5). Once surfactant surface 
film reaches tensions lower than 25mN/m (surface pressures higher than 45mN/m) during 
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compression, it folds through three-dimensional transitions, creating a multilamellar reservoir 
excluded from the interface. Folded layers maintain association with the interfacial films and 
contribute to its mechanical stabilisation at the minimal tensions (or maximal pressures). At this 
stage, protein SP-C seems to facilitate the folding of interfacial films, as it appears to induce 
membrane curvature58, the exclusion of certain lipids and lipid/protein complexes from the 
interface47, and the formation of three-dimensional phases . SP-B, on the other hand, stabilises 
the interfacial film by endorsing formation of membrane-membrane contacts59, 60, 61, providing 
mechanical stability to compressed multi-layered films. 
 
Figure 5: Interfacial behaviour of pulmonary surfactant. Scheme representing the complex structure of the 
interfacial multi-layered membrane-based film established by pulmonary surfactant at the respiratory surface. 
The main lipid and protein components are represented as they would be assembled in surfactant structures 
according to current models. 
Upon expansion, SP-B and SP-C are thought to promote insertion of new-coming surfactant 
and re-spreading of phospholipids from the reservoirs back into the interface28, 30, 61. Over the 
continuous compression-expansion cycles at the highly oxidative environment of the respiratory 
spaces, surfactant components are progressively altered and reorganised loosing activity. This 
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used and spent material needs to be removed from the alveolar spaces and replaced by new 
material continuously secreted by type II pneumocytes62. 
Sustainable Cleaning: recycling, clearing and degrading surfactant 
As essential as the presence of pulmonary surfactant lining the respiratory surface is to 
regulate its amount and quality throughout life. The balance between how much surfactant is 
produced and replenished is critical for the correct homeostasis of respiratory surface. When 
surfactant is freshly secreted by Type-II pneumocytes, it constitutes large aggregates that rapidly 
adsorb into the air-liquid interface. Upon compression-expansion cycles and as a consequence of 
the continuous contact with highly oxidative environment, this interfase-associated material suffers 
a compositional and structural transformation that ends in its conversion into lighter fractions or 
small aggregates63, 64. These fractions, mainly constituted by small vesicles enriched in low 
compressible surfactant compounds 65, have been considered as ‘used’ surfactant and need to 
be removed from the alveolar lining fluid65. To efficiently accomplish this process, which it is 
estimated to be rapid (10% per hour, approx.66), several mechanisms are involved. About 65% 
of the ‘spent’ surfactant is uptaken by Type-II pneumocytes and recycled67, around 20% is cleared 
by AMϕ15, 67, 68 while the rest 15% is lost through the upper airways via mucociliary escalator69. 
Recycling by type-II pneumocytes 
In an attempt to optimize the energy invested during surfactant synthesis, several 
mechanisms reuptake and reutilize the ‘spent’ surfactant components, which can be 
reincorporated into lamellar bodies in Type-II pneumocytes. The predominant recycling pathway 
proceeds via SP-A-dependant endocytosis, though SP-D70, 71 and SP-C58 seem to play additional 
roles promoting interconversions of the ultrastructure of surfactant. It has been reported that SP-
A, by binding to the membrane receptor P63/CKAP4, mediates internalization of phospholipids 
via clathrin-coated vesicles72. Once into the Type-II pneumocytes, phospholipids are arranged in 
early endosomes and subsequently transferred to lamellar bodies in a calmodulin-dependant 
manner73, while SP-A is rapidly re-secreted. In addition to this clathrin-mediated pathway, a 
nonclathrin actin-dependent endocytosis also happens independently to SP-A, yet it only 
represents the 3.5% of uptake74. Surfactant SP-D is able to interact with lipids through its CRD 
globular domain 75, 76, and break liposomes in vitro. It is hypothesized that SP-D could bind to 
surfactant membranes and promote their conversion, into small vesicles that could be easily 
internalised by type II pneumocytes but not macrophages70, 71. As a matter of fact, SP-D can 
interact with the membrane receptor Ig-Hepta/GPR116 expressed in type II cells. The presence 
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of SP-D in the alveolar lining fluid can be detected by this receptor, which seems to stimulate the 
recycling pathway but blocks synthesis77. Apart from recycling, which is the main pathway, these 
epithelial cells also export phosphatidylcoline (PC) through the lipid transporter ABCA1 and 
catabolise surfactant, mainly by the action of phospholipase A2 (PLA2), to maintain proper 
homeostasis62.  
Clearance by alveolar macrophages 
Macrophages are usually in charge of maintaining a low inflammatory context, ensuring the 
correct function of the tissue, performing non-immune, tissue-specific and homeostatic functions78. 
The microenvironment that macrophages encounter in the lungs is markedly fluctuant and 
peculiar. The continuous exposure to environmental antigens, hypoxia, oxidation, microflora, 
airway mucus, surfactant and epithelial cells that constantly change this microenvironment44, 
forces pulmonary macrophages (PMϕ) to adapt to such variable framework. Under homeostatic 
situations, PMϕ can be found in several locations where they play location-specific roles: 
bronchiolar submucosa, alveolar interstitium, vascular adventitia and luminal side of alveoli79. 
Particularly the latter harbours the so-called alveolar macrophages (AMϕ), while the other PMϕ 
are considered as a larger and more heterogenous group, the interstitial macrophages (IMϕ). 
Although the ontogeny of Mϕ is still unclear, the development of sophisticated tools to trace 
haematopoiesis in unperturbed organisms is helping to achieve unprecedented understanding of 
Mϕ biology. As in other tissue-resident macrophages, steady-state AMϕ are widely thought, at 
least in mice, to derive from foetal progenitors rather than by haematopoiesis from adult 
hematopoietic stem cells (HSCs)80, 81. However, it is known that during inflammation and stress 
situations IMϕ and adult monocytes-derived Mϕ migrate to alveoli and contribute to alveolar 
homeostasis44, 78. During embryogenesis, several waves of pre-macrophages seed the lungs under 
the expression of L-plastin, which promotes trans-epithelial migration and colonization of the 
alveolar space82. But it is not until the first contact with air at birth when the actual alveolar niche 
is generated. Then, circulating foetal monocytes83, 84 and already-there Mϕ85 start to acquire the 
AMϕ-specific characteristics and markers (i.e. CD11c or SiglecF). Production and secretion of 
granulocyte-macrophage colony-stimulating factor (GM-CSF) by type-II pneumocytes triggers the 
expression of peroxisome proliferator-activated receptor gamma (PPARγ), necessary for 
developing the alveolar Mϕ-specific transcriptomic profile, adapting the cells to the lung 
environment and acquiring a high lipid load function84, 86, 87. However, the Immunological Genome 
Project has shown that GM-CSF/ PPARγ pathway is present in other tissue-resident Mϕ. Thus 
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other signals such us the already-known Bach288, C/EBPβ89 and TGFβ90 must be present for the 
differentiation and function of AMϕ. 
Apart from being the guardians of the alveolar surface in continuous communication with 
the rest of the alveolar-resident and non-resident cells in order to maintain an adequate 
inflammatory/anti-inflammatory balance91, 92, 93, 94, 95, AMϕ are the cells in charge of pulmonary 
surfactant clearance15, 28, 62. Although a small part of the ‘used’ surfactant can be also degraded 
by type-II pneumocytes, AMϕ are the main actors. Orchestrated primarily by GM-CSFR/PPARγ 
signalling pathway, AMϕ have developed a sophisticated machinery to uptake, sort and 
metabolise surfactant lipids and proteins. Examples of proteins that are known to be part of this 
complex machinery, directly- or indirectly-controlled by GM-CSFR/PPARγ pathway, include: ABC 
transporters (ABCA1 and G1, implicated in cholesterol efflux), scavenger receptors class II such 
as SR-BI (involved in the metabolism of cholesterol) or CD36 (associated with cell adhesion, 
phagocytosis of apoptotic cells and metabolism of long-chain fatty acids), and lysosomal enzymes. 
Any disruption of these machineries could lead to an impairment of alveolar homeostasis causing 
pathologies such as pulmonary alveolar proteinosis (PAP) or pulmonary fibrosis. 
Surfctant-related pathologies 
As described above, the pulmonary surfactant system and a collection of cellular and 
molecular mechanisms work together to ensure the correct functioning and homeostasis of the 
lungs. Any inherited or acquired abnormality affecting this complex and perfectly coordinated 
system lead to both acute and chronic respiratory pathologies. Some of these anomalies, 
depending on the pathogenic context and age, ultimately end in different clinical syndromes such 
as neonatal respiratory distress syndrome (NRDS), acute respiratory distress syndrome (ARDS), 
interstitial lung diseases (IDL), surfactant metabolism dysfunctions (SMD), or combinations of 
them. 
NRDS, also known as respiratory distress syndrome (RDS), is related to the absent of 
surfactant at the moment of birth. In preterm new-borns this lack of surfactant derives from 
immature lungs, as pulmonary surfactant is secreted during the last weeks of gestation. This can 
be easily prevented or reverted nowadays by intratracheal administration of an exogenous 
surfactant (surfactant replacement therapy; SRT), Exogenous surfactant not only restores the 
deficiency but contributes to stimulate the production and secretion of endogenous surfactant. 
surfactant by pneumocytes. In parallel, mothers at risk of premature delivery are usually treated 
with corticoids to trigger surfactant production in the baby. Completely different is ARDS, which is 
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associated to lung injury and inflammation and characterised, in children and adults, by interstitial 
and bloodstream fluid leakage into the into the alveolar spaces, complicating or preventing 
respiration. Some of the blood components and inflammatory mediators inactivate surfactant by 
mechanisms that are only partly known, contributing to the pathology. However, surfactant 
dysfunction is only part of the alterations in ARDS lungs.  In enfants, ARDS can also be triggered 
by meconium or milk aspiration, or as a consequence of severe pneumonia96. Interstitial lung 
diseases, on the other hand, can be originated by several causes such as genetic mutations (i.e. 
SP-A genes: SFTPA1 and SFTPA2; or essential components of telomerases such as telomerase 
reverse transcriptase (TERT) or the telomerase RNA component (TERC)) 97, exposure to harmful 
agents (i.e. silica, asbestos, tobacco smoke or some medications) or autoimmunity. These 
pathologies ultimately end in scarring (fibrosis) and, consequently, stiffness of the lungs, hindering 
the process of breathing and finally producing respiratory failure. 
When the GM-CSFR/PPARγ pathway is altered in AMϕ, either by mutations or auto-
antibodies97, the metabolism of pulmonary surfactant fails and it is accumulated into the alveolar 
spaces. This aberrant accumulation of surfactant, which cannot properly accomplish the 
biophysical functions, is known as pulmonary alveolar proteinosis (PAP)98. Apart from being 
unfunctional, such amounts of lipids and surfactant proteins obstruct alveolar airspaces impeding 
gas exchange and triggering the inflammation process. Nowadays, the treatment consists in 
carrying out bronchoalveolar lavages to remove all surfactant debris. However, this therapy is 
highly invasive and unpleasant for the patient. Hence, other alternatives such as AMϕ 
transplantation are being investigated in mice models with promising results99, 100. 
Mutations in the SP-B gene usually result fatal as, this protein is essential for surfactant 
synthesis, packing in LB, ultrastructure and interfacial activity, apart from contributing to proSP-C 
maturation. Mutations in the ABCA3 gene are lethal as well, as this transporter is equally required 
for LB biogenesis. Deficiencies and abnormalities in ABCA2 have been related to severe diseases 
in the lungs associated with surfactant homeostasis such as anomalous LBs, dysfunctional 
pulmonary surfactant or congenital PAP . Finally, although mutations in SP-C gene are not lethal 
at first instance, they produce several pathologic phenotypes such as fibrosis, inflammation, higher 
susceptibility to infection and in the worst cases, interstitial diseases ending in respiratory failure 
at variable ages. 
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Therapeutic surfactants 
Since Mary Ellen Avery and Jere Mead realized that the hyaline membrane disease (current 
RDS) was due to a deficiency in pulmonary surfactant101, the idea of a surfactant replacement 
therapy (SRT) emerged. The first approach was developed using a synthetic surfactant made of 
only lipids, but resulted to be noneffective as a consequence of the lack of pulmonary surfactant 
proteins. Without these proteins, surface active lipid films are simply not formed and SRT has no 
effect102. In the 1970s, natural surfactants obtained from animal sources, principally bovine and 
porcine, started to be studied showing clear clinical improvements in rabbits103, 104 and lambs105. 
Consequently, in the 1980s several clinical trials were performed in neonates and soon after 
natural surfactants were established as an efficient treatment for NRDS106, 107. 
Nowadays there are numerous clinical surfactants obtained from porcine and bovine sources 
by mincing lungs (Curosurf® from Chiesi Farmaceutici; Survanta® from Abbot Laboratories) or 
by performing saline bronchoalveolar lavages (Surfacen® from CENSA; Infasurf® from Forest 
Laboratory; Alveofact® from Boehringer Ingelheim; Bles® from BLES Biochemicals). Although 
they present differences related with composition and functional, morphological, interfacial and 
biochemical features 42, all of them are approved for treating Respiratory Distress Syndrome by 
SRT. 
Nonetheless, these animal-derived surfactant preparations are relatively susceptible to 
inactivation, may present substantial batch-to-batch variations, are expensive to produce and 
supplies are limited. An additional major problem is the non-null possibility of animal-to-human 
transmission of potential pathogenic agents. Hence, other non-animal preparations that could 
allow producing surfactant in large quantities at reasonable cost while controlling composition and 
reducing inactivation/susceptibility are preferred. In this sense, entirely synthetic surfactants are 
currently proposed as a potential choice, but some considerations are critical regarding alveolar 
stability and appropriate performance in vivo. As mentioned, not only lipids, specially DPPC, but 
also the hydrophobic proteins SP-B and SP-C, or at least analogues of these proteins, are essential 
to sustain proper surfactant dynamics 102. This was the reason why Exosurf®, the first synthetic 
surfactant formulation designed by GlaxoWellcome to contain only lipids, was not as effective as 
animal-derived surfactants 108. The complex lipid composition of pulmonary surfactant and the 
troubles derived from production of effective SP-B and SP-C analogues make the production of 
synthetic surfactants with clinical application still challenging and not resolved issue. 
In spite of the difficulties, there are some advances. Different SP-B and SP-C analogues 
have been synthetized emulating some structural motifs and  biophysical properties of the native 
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proteins, exhibiting a reasonably good behavior 109. Thus, new surfactant formulations are 
emerging in the recent years. The KL4-based surfactant 
110, Surfaxin®, is the unique entirely 
synthetic surfactant that has reached the market and is indicated for the prevention of RDS in 
preterm infants. Venticute®, a surfactant containing recombinant SP-C 111, has been studied in the 
VALID trial, a multi-national clinical phase III investigation, but has not been approved yet as no 
benefits were observed in mortality rate or blood oxygenation, probably because of the absence 
of SP-B 108. Another synthetic surfactant that shows promising effects is CHF 5633, which is 
composed by two phospholipids (DPPC and POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol)) and both SP-B and SP-C analogues. In comparison with an animal derived 
surfactant (Curosurf®), CHF 5633 seems to produce significant benefits in premature lambs 
whose endogenous surfactant is inactivated 112. 
Pulmonary surfactant as a shuttle for drug delivery 
The exceptional properties of pulmonary surfactant were early suggesting the idea of using 
it to transport therapeutic agents deep into the distal airways. The hydrophobic components of 
PS provide a perfect environment to host poorly soluble drugs and nanocarriers, and bring about 
the opportunity to accomplish novel and creative approaches for treating not only respiratory 
pathologies, but also others alongside the body 4. Furthermore, the ability of PS to spread along 
the air-liquid interface could help to deliver drugs directly into the alveolar region, something 
difficult to achieve using current strategies. The combination of drugs or nanocarriers with PS can 
hide and protect them from clearance in the lung. As a consequence, it could facilitate reduction 
of doses, secondary effects and costs, as well as producing synergistic effects while increasing 
local effectiveness. On the other hand, in a similar manner to the exclusion of pulmonary surfactant 
components from the interfase upon compression-expansion cycling during breathing, the 
additional passengers that may share the interfacial trip could be progressively released once at 
the alveolar spaces. Altogether PS-based drug delivery could open new avenues to more 
personalised, precise and efficient therapies in respiratory medicine. 
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Figure 6: Schematic representation of an alveolus and associated blood capillary showing the vehiculizing 
strategy concept.  
The feasibility of using pulmonary surfactant as a carrier was demonstrated during the 
1990s. In 1999, Herting et al. demonstrated that administering a specific IgG combined with 
Curosurf® to newborn babies suffering from group B streptococcal (GBS) pneumonia, improved 
lung function and decreased bacterial growth, with no negative effects in PS nor IgG actions 113. 
Since then, extensive work with antibiotics114, 115, 116, antimicrobial peptides117, recombinant 
adenoviral vectors118, antioxidant enzymes119, corticosteroids120, 121, 122 or nanocarriers123, 124, 125, 
126, 127, 128 combined with surfactant, have demonstrated synergistic effects and promising 
perspectives not only in vitro and in silico, but also in vivo, evidencing the unlimited possibilities 
of pulmonary surfactant as a drug delivery system. 
Key aspects in surfactant-assisted drug delivery 
The use of pulmonary surfactant as a drug delivery system calls requires keeping in mind 
several important aspects concerning the way it is administered and how the lung environment 
and the expected target will condition the strategy to follow. 
i) Friendly administration: 
The current method of clinical PS administration is based on intratracheal instillation. Such 
methodology requires hospitalization and intubation, something that could produce acute airway 
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obstruction, hypoxia and bradycardia129, is unpleasant for the patient, takes a lot of time and is 
expensive. The possibility of using non-invasive and patient-friendly formulations is strongly 
preferred and is now an intensive matter of research. Administering synthetic PS as a dry powder 
was briefly studied during the 1980s 130, 131. Judging by the latest advances in dry powder inhalers 
(DPIs) for drug delivery 132, this method could be a promising strategy, but no recent studies have 
evaluated the possibility to deliver dry preparations of synthetic or natural PS. Nebulized 
formulations were tested with no satisfactory results in the 90’s 133, but the recent advances in 
nebulizing technology have considerably improved surfactant nebulization. Furthermore, recent in 
vivo studies have shown promising results during continuous positive pressure ventilation (CPAP) 
in spontaneous breathing rabbits  (synthetic surfactant)134 and preterm lambs (Curosurf®, a 
porcine-derived surfactant)135, 136, where surfactant was better distributed into the whole lung and 
some physiological parameters (oxygenation and lung function) were also improved with respect 
to intratracheal instillation136. 
ii) Endogenous surfactant status 
When the pathological condition requiring intervention includes an impairment of the 
endogenous surfactant function, the exogenous surfactant must work properly and possess 
intrinsic prophylactic and therapeutic effects by itself, regardless the addition of drugs or combined 
nanosystems. It is widely accepted that surfactant replacement therapy is effective in preventing 
different lung diseases such as NRDS96 or bronchopulmonary dysplasia (BPD)137, and can 
ameliorate certain cases of acute lung injury (ALI)138 and even asthma attacks139. Simultaneously, 
different anti-inflammatory and antibiotic drugs are being used to treat these diseases or to 
alleviate inflammation derived from the respiratory support techniques used for SRT120, 121, 122, 140. 
Therefore, a combination of both is starting to be used with promising results. It is important to 
take into account that the pathogenic surfactant-inactivating context may also affect the 
therapeutic surfactant or surfactant/drug preparation. Thus development of inactivation-resistant 
surfactants may potentiate therapeutic strategies in these cases. 
On the other hand, when the endogenous surfactant works properly, a dose of exogenous 
surfactant can be used as a mere excipient to vehiculize the therapeutic agent, with interfacial 
adsorption and spreading properties being the most important properties that the surfactant 
vehicle should maintain. In this sense, the optimization of synthetic surfactants gains prominence, 
where PS composition and properties should favour an efficient drug delivery, and not necessarily 
that much the intrinsic surface-stabilization properties. Nevertheless, surfactant overdose may 
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impair the phagocytic activity of lung macrophages 141 and result in acute airway obstruction or 
problems with fluid and electrolyte balance. Thus, the surfactant dose here is crucial and need to 
be optimised to maintain the vehiculizing properties while reducing the potential toxicity. 
iii) Nature of the treatment 
Although pulmonary surfactant constitutes a highly favourable environment for transporting 
hydrophobic agents directly dispersed into it, it is not a proper container for hydrophilic 
compounds due to its intrinsic dynamism and the high porosity of its membranes 32, 33. New 
advances in nanotechnology could allow the generation of optimized nanocarriers that could 
encapsulate hydrophilic and hydrophobic drugs while properly interacting and travelling associated 
within pulmonary surfactant. 
iv) Mutual surfactant/drug/nanocarrier effects 
The biophysical effects of antituberculotic drugs on PS surface performance have been 
studied using DPPC monolayers as a model. The research performed by Chimote and Banerjee in 
2004 combined DPPC with either isoniazid (INH) or a triple drug mixture 
(INH/rifampicin/ethambutol) and observed that both combinations achieved superior surface 
properties than DPPC alone 142. More recently, another study evaluated the impact of rifampicin 
(Rif) on the biophysical activity of Curosurf® and Survanta®. These experiments, performed in a 
pulsating bubble surfactometer, showed that Curosurf® was able to incorporate higher amounts 
of Rif and that the antibiotic interfered with both therapeutic surfactants in a concentration-
dependent manner 143. Additionally, other antibiotics (amikacin, cefepime and colistimethate 
sodium) have also been studied, revealing the impact of the drugs in PS and vice versa. Amikacin 
and cefepime did not affect PS while colistimethate did. When the impact of PS on antibiotics 
were evaluated, amikacin was the only antibiotic that was no affected 144. 
Understanding the effects that nanocarriers have on PS is essential to optimize the design 
and production of improved drug delivery systems through the airways, not only to avoid 
deleterious effects but also to optimise synergistic effects from their combination. Drugs and 
nanocarriers can directly or indirectly affect the functional properties of surfactant. They could 
induce pulmonary inflammation145, 146, oxidative stress and lipid peroxidation147, 148, indirectly 
leading to PS impairment149, 150. The transference of surfactant components, especially the 
hydrophobic and positively charged proteins SP-B and SP-C, to nanocarriers during the so-called 
corona formation (adsorption of a layer of molecules at the surface of the nanostructures) is in 
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essence the factor determining the direct detrimental effects of nanocarriers on surfactant124, 151, 
152, 153, 154. It is known that the hydrophobicity, size and surface charge of nanocarriers determine 
the formation of the surfactant corona155. Furthermore, the adverse effects of certain nanocarriers 
also depend on the administered dose; at low doses the initial interfacial adsorption and dynamic 
surface tension were not negatively affected, while at higher loads they were 152. 
v) Local or peripheral target 
The target is another important aspect to consider, which defines the development of novel 
drug delivery approaches. For instant, if the target is to treat tuberculosis, drug vehiculization 
should pursue reaching the alveolar region and then internalization by AMϕ, where Mycobacterium 
tuberculosis completes its life cycle. On the other hand, if the target is a different location over 
the body, drug delivery needs to go through several barriers including type I pneumocytes, the 
capillary endothelium and the immune system. Therefore, it is crucial to understand 
pathophysiology and homeostasis in the lung to design, optimize and evaluate novel drug delivery 
strategies. 
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Levering the exceptional interfacial properties of the pulmonary surfactant system, the main 
objective of this Thesis is to explore the potential of pulmonary surfactant to vehiculize different 
therapeutic agents through the airways using the air-liquid interface, setting the basis of a novel 
and less-invasive strategy, the interfacial therapy. In order to accomplish this objective the 
following specific aims are proposed: 
1. Stablish and optimize different strategies to combine several molecules of medical interest 
with clinical and synthetic pulmonary surfactants.  
2. Evaluate the possible detrimental effects of the vehiculized molecules on the interfacial 
behaviour of pulmonary surfactant. 
3. Verify the vehiculizing potential of different surfactant formulations through in vitro air-
liquid interfaces. 
4. Determine the implications of compression-expansion breathing dynamics on the 
interfacial vehiculization of drugs by pulmonary surfactant. 
5. Confirm the feasibility of surfactant-assisted interfacial vehiculization in vivo, determining 
the main factors implicated and testing its potential synergistic surfactant/drug therapeutic 
effects. 
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In this section, only the most general materials and methods are described. The specific 
techniques, procedures and materials used to perform the experiments on each chapter are 
conveniently explained on the corresponding chapter. Unless otherwise stated, all chemicals were 
purchased from commercial suppliers (Sigma-Aldrich®, Merck KGaA or Macron Fine 
Chemicals™) and used without further purification. Water was from a Merck-Millipore Direct-Q3 
purification system. 
PULMONARY SURFACTANT SYSTEMS: THE VEHICLES 
Native pulmonary surfactant 
The isolation of native surfactant was carried out from bronchoalveolar lavages (BAL) 
obtained from porcine lungs, following a protocol optimized at the laboratory 149, 156, 157. Concisely, 
BALs were performed by introducing a buffer solution (5mM Tris, 150mM NaCl, pH 7.4) through 
the trachea, while massaging vigorously the lungs. Each lavage was filtered to remove the tissue 
debris and centrifuged at 1000g, 4 °C during 5 minutes to eliminate cells and debris. Then, it 
was ultra-centrifuged in an angular rotor at 100,000g during 1 hour at 4 °C. The pellet was 
resuspended and ultra-centrifuged in a discontinuous NaBr density gradient during 2 hours at 
120,000g in a swinging-bucket rotor. Finally, the purified PS complexes, located between the 0% 
and 13% NaBr layers of the gradient, were obtained and homogenised in NaCl 0.9%, storing 
them as small aliquots at -80 °C until used (see Figure 7). 
 
Figure 7: Density gradient used to purified pulmonary surfactant. It allows for separating the surfactant 
complexes from the rest of material with a higher density, mainly rests of erythrocytes and white blood cells. 
Poractant Alpha (Curosurf®) 
Poractant Alpha (Curosurf® or Csf) is a modified natural surfactant produced by 
reconstitution of a hydrophobic lipid/protein fraction obtained from minced porcine lungs. It is 
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commercialised by Chiesi Farmaceutici (Parma, Italy) for clinical use. It contains polar lipids and 
the hydrophobic surfactant proteins (SP-B and SP-C), with no cholesterol, and is served at a 
phospholipid concentration of 80 mg/mL. When needed, it was diluted with a buffer solution 
(5mM Tris, 150mM NaCl, pH 7.4). 
CHF5633 
CHF5633 is a fully synthetic surfactant containing equimolar proportions of 
dipalmitoylphosphatidylcholine (DPPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
(POPG) and peptide analogues of the hydrophobic surfactant proteins SP-B 
(CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS) and SP-C 
(IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL) 112. It was also provided by Chiesi, at a concentration 
of 80 mg/mL. When needed, it was diluted with a buffer solution (5mM Tris, 150mM NaCl, pH 
7.4). 
Organic extracts 
Organic extracts (OE) from NS, Poractant alfa or CHF5633 were obtained as described by 
Bligh and Dyer 158. Firstly, proteins were flocculated by incubating 30 minutes at 37 °C in the 
presence of chloroform and methanol mixed at the proportions chloroform/methanol/water 1:2:1 
(v/v/v). To allow the formation of two phases, a new volume of chloroform and water were added 
to the mixture and then centrifuged at 3000g and 4 °C during 5 minutes. In order to rescue the 
maximum amount of PS components, successive lavages with chloroform and methanol were 
performed. After each lavage, the hydrophobic components of NS were collected from the organic 
phase at the bottom and storage at -20 °C until used. 
MEMBRANE-BASED VEHICLES 
Multilamellar vesicles and organic extract reconstitution 
To prepare multilamellar vesicle (MLV) suspensions, an appropriate volume of a 
chloroform/methanol (2:1 v/v) solution of the DPPC/POPG (7:3 w/w) mixture (lipids obtained 
from Avanti Polar Lipids Inc.), or of the organic extracted materials, was dried under a nitrogen 
stream and then under vacuum for two hours to remove organic solvent traces. The dried films 
were then hydrated with a buffered solution (5 mM Tris, 150 mM NaCl, pH 7.4) at 45 °C, a 
temperature above the melting temperature of all the lipids in the mixtures (Tm = 41°C for DPPC). 
The hydration was accomplished in one hour with vigorous shaking every 10 min. 
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Large unilamellar vesicles 
Large unilamellar vesicles (LUVs) of DPPC/POPG (7:3 w/w) were prepared by extruding 
MLV suspensions several times through polycarbonate membranes of 100 nm pore size 
(Whatman® Nuclepore Track-Etched Membranes, 19mm diameter, 0.1µm pore) in a mini-
extruder (Avanti Polar Lipids Inc.), to obtain a relatively homogeneous suspension of unilamellar 
vesicles of ca. 100nm diameter. The extrusion was also carried out at 45°C. 
PASSENGERS 
Corticosteroids 
Beclomethasone dipropionate (BDP), in the form of powder, or taking part of the aqueous 
suspension Clenil, was provided by Chiesi Farmaceutici (Parma, Italy). Budenoside (BUD) 
powder was also obtained from Chiesi, and its solubilised formulation (Pulmicort) was purchased 
from Astra Zeneca (Södertälje, Sweden). To determine the amount of the steroid incorporated 
into the surfactant membranes, an aliquot of 10 µL of BDP-containing surfactant was diluted in 
1 mL of methanol and the absorbance of the solution was measured at 235nm (ε235= 0.0704 
M-1cm-1). The fluorescent derivative of BDP (BANB) was synthetized and provided by Prof. 
Guillermo Orellana’s laboratory (Department of Organic Chemistry, Faculty of Chemistry, 
Complutense University, Madrid, Spain). The synthesis is briefly summarised in the Vehiculization 
troughs section of the Chapter I (for additional details, see supplementary in 159). 
Tacrolimus 
Tacrolimus (TAC or FK506, +98%) was provided by Sinoway Ind. Co. (China) in the form 
of powder. The fluorescent derivative (TAC·NileBlue) was synthetized by Prof. Guillermo Orellana’s 
laboratory following an analogous method described by Glahn-Martínez et al. 160 and provided in 
the form of powder. 
INCORPORATION OF THE PASSENGERS INTO SURFACTANT MEMBRANES 
In order to incorporate the corticosteroids into the surfactant preparations, three different 
protocols have been followed. In a first type of experiments, the proper amount of corticosteroid, 
diluted in methanol, was dried on the wall of plastic tubes under a nitrogen flow. Then a volume 
of 50 µL of different surfactant or lipid suspensions were added into the tubes and incubated for 
30 min at 37°C, with stirring every 10 min. Alternatively, BDP or BUD were directly incorporated 
into organic extracts from NS or Poractant alfa and the mixture was then dried and resuspended 
in saline following the same protocol than used for the formation of membranes (1h, 45 °C, 
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vigorous shaking every 10 min, see section Multilamellar vesicles and organic extract 
reconstitution). In a third alternative, BDP or BUD were incorporated into clinical surfactants 
Poractant alfa or CHF5633 upon incubation with clinical formulations of the corticosteroids such 
as Clenil® or Pulmicort®. For some experiments, Clenil-like corticosteroid emulsions were 
previously prepared by combining the excipients of Clenil to solubilize the proper amount of BDP, 
the mixture BDP/BANB (see below), or BUD. 
In the case of TAC, it was previously diluted in methanol and then directly incorporated into 
the DPPC solution in chloroform/methanol (2:1 v/v) or the organic extract obtained from NS, as 
convenience. When needed, the mixtures were conveniently reconstituted in a buffered solution 
as described above in the section Multilamellar vesicles and organic extract reconstitution.  
PHOSPHOLIPID QUANTIFICATION ASSAY 
The concentration of phospholipid was evaluated following a protocol established by Rouser 
et al. in 1966 161. It is a colorimetric methodology based on the quantification of the phosphorous 
present in phospholipids after conversion to inorganic phosphate using perchloric acid at 260 °C. 
The colorimetric reaction took place at 100 °C for 7 minutes after addition of water, ammonium 
heptamolybdate 2.5% (w/v) and ascorbic acid 10% (w/v). Finally, the absorbance at 820 nm of 
each sample was determined in a UV/Visible spectrometer (Beckman DU840) and interpolated 
in a standard curve made with inorganic phosphate (KH2PO4). Due to the heterogenic 
composition of pulmonary surfactant, the molecular weight of DPPC (734.04 g/mol) was 
considered to calculate its mass as it is the most abundant phospholipid in the pulmonary 
surfactant system. 
SURFACE TROUGHS 
In the present Thesis the traditional Langmuir-Blodgett and Wilhelmy troughs have been 
used to design and optimize two novel in vitro models of the respiratory air-liquid interface, one 
static and the other dynamic. The idea is to study the potential use of pulmonary surfactant as a 
drug delivery system and the implications of compression-expansion breathing-like cycles on this 
novel strategy. Figure 8 shows a schematic representation of a basic surface trough and the 
elementary components. The surface pressure sensors having a Wilhelmy plate were purchased 
from NIMA technologies (Coventry, UK). The Wilhelmy plate (21 mm perimeter; 24 mm x 10 mm 
x 0.5 mm) was made with a grade 41 Ashless Filter Paper (Whatman®, GE Healthcare Life 
Sciences). The Langmuir-Blodgett trough was also purchased from NIMA technologies. The 
Wilhelmy trough was designed in collaboration with the UCM Research Support Centre (CAI). 
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Both the static and dynamic setups will be further explained in the Key techniques section of 
Chapter I and Chapter II, respectively. 
 
Figure 8: Schematic representation of a surface trough.  
FLUORESCENCE SPECTROSCOPY 
In order to investigate the vehiculizing potential of pulmonary surfactant, the molecules 
transported by pulmonary surfactant were measured in both donor and recipient troughs using 
an Aminco Bowman Series 2 spectrofluorometer. The two fluorescent drug derivatives evaluated 
in this thesis were labelled with an analogous of NileBlue, a far red fluorescent dye (λexcitation = 
590 nm; λemission = 650 nm). The emission spectra were taken at 25 °C and the sensitivity was 
set differently for the samples from the donor and recipient troughs as considerably more amount 
of fluorescent molecules were in the donor. Every sample were stored at 4 °C in dark conditions 
until measured to avoid the photobleaching of the sample. 
FLUORESCENCE MICROSCOPY 
To analyse the structure of DPPC monolayers and surfactant films, images were taken from 
films doped with 1% (molar ratio) NBD-PC (Molecular Probes®, Thermo Fisher Scientific), 
transferred as Langmuir-Blodget films onto glass coverslips in continuous compression conditions 
(barrier speed: 25 cm2/min; deeper speed: 5 mm/min). Images were acquired with an ORCA R2 
10600 (Hamamatsu Photonics K.K.) camera coupled to the epifluorescence microscope Leica 
DM 4000B (Leica Microsystems). The fluorescence microscope is an optical microscope that 
uses fluorescence to observe the sample of interest with the light source coming from the top 
(epifluorescence) and falling upon the upper side of the sample. In some experiments, the 
fluorescent derivative of tacrolimus was added conveniently as a trace (1% by mass with respect 
to lipids); when the amount of drug was higher than 1% by mass, the rest was completed with 
non-modified drug. 
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For the experiments performed in vivo to determine which type of cells internalised 
tacrolimus, the images were taken under the Olympus IX-81 inverted fluorescence microscope at 
the laboratory of Prof. Jahar Bhattacharya in Columbia University in New York City. In this case, 
the fluorescent derivative of tacrolimus was used to track the drug over the lungs (1.5% by mass 
with respect to lipids). 
ATOMIC FORCE MICROSCOPY 
This technique scans the surface of a sample measuring its topographical profile. A tip 
connected to a flexible structure (cantilever) interacts with the sample and oscillates upon the 
differences in height. The oscillation is detected by the reflexion of a LASER focused on the top 
of the tip (Figure 9). This technique allows analysing the lateral organization of phospholipid films 
and the three-dimensional structures formed associated to pulmonary surfactant. The preparations 
were made following the same method as used for epifluorescence microscopy but transferring 
the films to mica plates, instead. Mica is a multi-layered structure whose layers are atomically flat 
and very easy to exfoliate, offering a perfect background for topographical profiling. The 
measurements of DPPC monolayers were taken by using an AFM MultiMode SPM (Digital 
Instruments, Inc./Veeco Metrology Group) at the UCM Research Support Centre (CAI) for 
Microscopy in Madrid  (Spain). In the case of the experiments performed with surfactant films, 
the measurements were taken using a NanoWizard II AFM (JPK Instruments, Berlin) at the Unidad 
de Biofisika (CSIC, UPV/EHU) in Bilbao (Spain) in contact mode, using silicon nitride tips and 
cantilevers E and D. The data were processed using the JPK Data Processing software. 
 
Figure 9: Schematic representation of an AFM. A) Representation of the main components of an AFM. The AFM 
scans the surface of a sample and determine the topographical profile. This is detected by means of the reflexion 
of a LASER that is focused on the top of a tip placed at the end of a flexible structure (cantilever). The surface-
promoted movements of the cantilever change the reflexion angle of the LASER and it is translated into 
differences in height, obtaining a topographical profile. B) Correspondence of the topographical profile with the 
structures observed in phospholipid samples. 
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The results included in the present chapter were published in the article: 
o Hidalgo, A., F.; Fresno, N.; Orellana, G.; Cruz, A.; Perez-Gil, Jesús. Efficient 
interfacially-driven vehiculization of corticosteroids by pulmonary 
surfactant. Langmuir 2017, 33 (32), 7929-7939. 
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INTRODUCTION 
The development of innovative drug delivery strategies is essential to increase the efficiency 
and efficacy of therapies, while targeting drugs to precise locations avoiding systemic side effects. 
As aforementioned, more than 90% of new drugs are poorly soluble in water. Therefore, the 
investigation of new strategies to facilitate solubilization of new generation drugs and to establish 
novel sites for drug entry is acquiring high importance nowadays. This chapter presents a proof 
of concept of the vehiculizing capacity of pulmonary surfactant to establish the basis of a protocol 
to optimise the combination of PS and drug passengers. Regardless of the drug, nanocarrier or 
whatever passenger to be vehiculized by surfactant, this work proposes that the optimization of 
the vehiculization process requires the  systematic characterization of three essential issues in 
vitro prior to evaluate vehiculization in vivo: (a) how the therapeutic agent can be incorporated 
into natural or synthetic surfactants, (b) whether the presence of the drug affect surfactant 
function, and (c) whether the combination with surfactant enables the distribution of the drug 
over the air-liquid interface. 
In this study, two hydrophobic drugs, the corticosteroids beclomethasone dipropionate 
(BDP) and Budesonide (BUD), were selected as an example to show the vehiculizing potential 
of pulmonary surfactant through the respiratory air-liquid interface and to design the general 
protocol to optimize it. These compounds are anti-inflammatory drugs widely used to treat 
different respiratory diseases, such as asthma or bronchopulmonary dysplasia (BPD)162, 163, 164. In 
particular, the combination of BDP and PS has shown synergistic effects to reduce certain markers 
of inflammation122, improving respiratory function in preclinical models 121. Moreover, clinical pilot 
studies utilized intra-tracheal instillation of BUD suspended in pulmonary surfactant to improve its 
delivery to the lung periphery for the prevention of BPD. They reported a substantially reduced 
incidence of BPD with no observed immediate or long-term adverse effects 165. For local action in 
the lungs, BDP or BUD are currently delivered in the form of aerosol, but new systems are needed 
to reduce systemic exposure, lung clearance and the total dosage, as well as to reach other target 
locations such as distal airways more efficiently. Nowadays several clinical surfactants obtained 
from bovine or porcine sources are being used to treat preterm new-borns4, 42, and new synthetic 
preparations are under development112, 166. Therefore, it is crucial to investigate and compare the 
abilities of clinical surfactants of different nature to transport different passengers as these 
corticosteroids. 
In the current work, a surfactant preparation produced from minced porcine lung tissue 
(Curosurf®), and,  CHF5633, a fully synthetic surfactant containing surrogates of hydrophobic 
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proteins SP-B and SP-C, have been selected and compared with whole native surfactant purified 
from porcine lung, with respect to their capabilities to incorporate and vehiculize BDP or BUD over 
the air-liquid interface. The interaction of BDP with PS membranes was first studied to optimize 
incorporation of corticosteroids into surfactant complexes. Then, the effect of BDP or BUD on the 
PS behaviour was analysed using a Captive Bubble Surfactometer. Finally, the spreading 
properties and corticosteroid transporting potential of PS was evaluated with selected drug/PS 
combinations applied in a novel setup that couples two traditional Wilhelmy troughs connected by 
an interfacial bridge. 
KEY TECHNIQUES 
Captive Bubble Surfactometer 
In 1989, Schurch et al. published a method that somehow reproduced the interfacial 
dynamics of an alveolus in vitro, the captive bubble surfactometer (CBS). It allows to evaluate 
surfactant activity at the surface of a millimetre-sized air bubble confined into an aqueous solution. 
The bubble is subjected to several compression-expansion cycles, mimicking breathing dynamics 
at physiological conditions of temperature, humidity and pH167. As explained above, pulmonary 
surfactant prevents pulmonary collapse during the expansion of alveoli and needs to withstand 
continuous compression and expansion dynamics in vivo. In order to ensure that any extra 
compound combined with surfactant does not alter its functionality, every surfactant/drug 
combination needs to be tested under physiologically-relevant conditions in the CBS. 
This unique device allows to perform four different sequential experiments to (i) evaluate 
the initial adsorption to the air-liquid interface (initial adsorption), (ii) test the post-expansion 
adsorption and re-spreading once the bubble is subjected to a first expansion (post-expansion 
adsorption), (iii) analyse the behaviour of interfacial films during 4 slow compression-expansion 
cycles, where the bubble is reduced or enlarged in discrete steps (quasi-static cycles), and (iv) 
study the behaviour of the films during 20 cycles of continuous compression and expansion 
preformed during 1 minute, a rate similar to the normal breathing rate in humans (dynamic 
cycles). 
To start the assay, 200 nL of the sample to be tested at a lipid concentration of 25mg/mL, 
is injected into a buffered subphase containing sucrose to increase density (150 mM NaCl, 10% 
sucrose (p/v), 5 mM Tris, pH 7.4) inside a cylindrical sealed thermostatised chamber. The 
injection liberates the surfactant close to the interface of a small air bubble (around 4-5 mm 
diameter), previously formed and settled on the base of an agarose cap that acts as a hydrated 
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support. The bubble can then be compressed and expanded by mean of a piston driven by a 
computer-controlled engine (see Figure 10). Volume, surface area and surface tension can be 
calculated and monitored along the whole experiment by measuring the height and the diameter 
of the bubble. The experiment is recorded by a video camera and then analysed by a specific 
software168, 169. 
 
Figure 10: Operational scheme of captive bubble surfactometer (CBS) experiments. CBS experiments start with 
the injection of a small volume (typically 200 nL) of concentrated surfactant (25 mg/mL phospholipid) near the 
surface of a millimetre-sized air bubble formed in a thermostated chamber containing a buffered dense saline 
solution. After 5 min to allow surfactant for adsorption and further 5 min after expansion of the bubble to 
facilitate surfactant spreading to form a surface active film, the chamber is closed and subjected to compression-
expansion cycles mimicking breathing dynamics. 
Vehiculization troughs 
In order to evaluate the ability of pulmonary surfactant preparations to efficiently travel and 
vehiculize drugs along the air-liquid interface, a novel setup was designed in the laboratory based 
on the original Yu and Possmayer’s design170. This novel device, named double or vehiculization 
trough, mimics somehow a respiratory surface in vitro and consists of two surface troughs 
connected by an interfacial bridge (a hydrated No. 1 Whatman filter paper). A small volume of 
any surfactant sample, with or without the drug, can be deposited by injection into the aqueous 
subphase, or spreading or nebulizing directly onto the interface of one of the troughs (donor), 
which is assumed to mimic the upper airways. Once adsorbed into the donor interface, surfactant 
is expected to diffuse through the interfacial bridge (conductive airways) and reach the recipient 
trough (distal airways). This interfacial trip is continuously monitored by following the changes in 
surface pressure (or surface tension) in both donor and recipient troughs (see Figure 11). To 
control the experimental temperature, the set-up is confined in an isolated container and 
continuously thermostated. Subphase in both troughs usually consists in buffer (5 mM Tris, 150 
mM NaCl, pH 7.4) to maintain pH under control. 
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Figure 11: Concept of the vehiculization trough. Consisting of two different Wilhelmy troughs connected by an 
interfacial bridge, the vehiculization trough reproduces a respiratory surface in vitro. Pulmonary surfactant is 
deposited into the donor trough (upper airways) and is expected to travel interfacially through the interfacial 
bridge (conductive airways) to finally reach the recipient trough (distal airways). The process is continuously 
monitored by measuring the surface pressure in both donor and recipient troughs. 
Following this concept, several variants can be designed to approach specific situations. 
Although this device is highly versatile, there are three critical parameters that need to be 
considered when designing the experiments and analysing their results: surfactant concentration, 
surface area of the troughs and size of the interfacial bridge. Previous work in our laboratory 
showed that, under limiting conditions of surfactant concentration (<10 mg/mL), differences in 
spreading velocity were observed depending on the size of the interfacial bridge (data not shown). 
However, at the concentration used to perform the experiments in this Thesis (50 mg/mL), those 
differences are negligible. In this case, the recipient surface area is determinant and it is necessary 
to contemplate it when comparing experiments. The larger the recipient area, the longer time is 
needed for the surface pressure to start rising and reach the equilibrium surface pressure, as more 
material is required to cover the whole interfase. Concretely in this chapter, the donor surface area 
was 315 mm2; the recipient 106 cm2). 
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To evaluate if surfactant can transport any kind of passenger, it has to be detected it in the 
recipient trough. The election of the detection method not only depends on the passenger 
(fluorescence, HPLC, mass spectrometry, electrophoresis, microscopy, etc.), but also on the 
available amount at the recipient trough. As the trip depends on the concreted moment of 
molecular layers over the, the total amount of vehiculized molecules is limited by the recipient 
surface area. The larger the surface area, the higher the amount of molecules available for 
detection. Therefore, a method sensitive enough is required to detect the vehiculized entities in 
small quantities, otherwise there is a risk to incur false negatives. An additional possibility is to 
increase the amount of molecules collected from the interfase. 
In this Thesis, the most frequent method to detect the vehiculized drug was fluorescence, 
in many cases upon repeated collection of the material at the recipient interface. In this chapter, 
in order to follow the diffusion of corticosteroids between donor and recipient troughs, a 
fluorescent-labelled derivative of beclomethasone dipropionate (BANB, Figure 12) was prepared. 
The synthesis of BANB involves saponification of beclomethasone dipropionate (BDP) into 
beclomethasone, followed by oxidation of the latter with periodic acid to a carboxylic acid 
derivative (BC, Figure 12). Finally, conjugation of BC to an amine derivative of the strongly 
fluorescent dye NileBlue (ANB) is carried out by amidation, after activating the BC with a mixture 
of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole to provide the 
beclomethasone-Nile Blue conjugate (BANB, Figure 12). BANB was purified by column 
chromatography on silicagel upon eluting the raw product with a chloroform/methanol/NH4OH 
(6:1:0.1 v/v/v) mixture. The fluorescence (λex = 590 nm; λem = 650 nm) was measured in 
samples taken from both donor and recipient troughs using an Aminco Bowman Series 2 
spectrofluorometer. 
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Figure 12: Synthesis of the far-red fluorescent derivative of beclomethasone tagged with pseudo NileBlue 
(BANB). Reagents and conditions: (i) KHCO3, MeOH, 72 h, r.t.; (ii) H5IO6, dioxane/H2O, r.t., 48 h; (iii) 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC · HCl), amino pseudo Nile Blue (ANB) derivative, 1-
hydroxybenzotriazole (HOBT), Et3N, CH2Cl2, r.t., 24 h. 
RESULTS 
Incorporation of corticosteroids into surfactant membranes 
In order to evaluate the amount of drug that the different lipids systems were able to 
incorporate, an identical amount of BDP (100µg) was dried on plastic tubes and exposed to 
increasing total amounts of different lipid and lipid-protein suspensions, including NS and its 
organic extract, and MLVs and LUVs made of DPPC/POPG (7:3, w/w). After incubation at 37 C 
during 30 min shaking every 10 min, each mixture was separated into two fractions: (a) the 
membrane suspension bearing the solubilised drug and (b) the remaining drug on the tube walls. 
The amount of BDP was then evaluated by absorption measurements, where an aliquot of 10µL 
of BDP- or BUD-containing surfactant was diluted in 1mL of methanol and the absorbance 
measured at 235 nm (ε235= 0.0704 M-1cm-1). Figure 13 represents the percentage of BDP that 
was found associated to the membrane lipids as a function of the amount of lipid. The fraction of 
drug associated with lipid membranes rose following a linear trend, while the drug that remained 
on the tube decreased with a similar slope. 
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Figure 13: Incorporation of BDP into surfactant lipid and lipid/protein suspensions. The proportion of 
corticosteroid (100 g) incorporated (solid lines) and non-incorporated (dashed lines) from dried films into 
suspensions of NS, its organic extract, or MLV or LUV suspensions made of DPPC/POPG (7:3, w/w), has been 
plotted as a function of the concentration of phospholipid. Lines represent the linear plots that better fit the 
experimental data. 
To confirm whether the different lipid suspensions follow a similar saturation tendency as 
an evidence of the drug incorporation into the membranes, different amounts of BDP were 
exposed to identical lipid concentration (20mg/mL) of the different surfactant materials. Figure 
14A shows how each sample incorporates the drug following an apparent hyperbolic saturation 
curve. At lower drug/lipid ratios, LUVs of DPPC/POPG apparently captured more drug compared 
with the other samples. Suspensions of NS or of its OE followed very simillar trends, but capturing 
slightly less drug than pure lipid unilamellar suspensions. MLVs, on the other hand, were the 
samples capturing less drug at low drug/lipid ratios, likely because only the outer layers are 
effectively exposed to the drug. However, at higher drug/lipid ratios, MLVs tend to exhibit similar 
drug loading capacities than the other analysed preparations. In Figure 14B, the saturation curves 
of BDP incorporated into the clinical surfactants Poractant alfa and CHF5633, can also be 
compared. Interestingly, they exhibit similar ability to solubilize BDP than native surfactant or its 
organic extract, in both qualitative and quantitative terms. At lower drug/lipid ratios Curosurf® 
seems to incorporate more amount of BDP than CHF5633, in a similar manner to LUVs (see 
Figure 14). However, it saturates at lower amounts of BDP than any other assessed preparation. 
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Regarding CHF5633, it follows a similar tendency to native surfactant or its organic extract (see 
Fig. 6), being able to incorporate more amount of BDP than Curosurf®. 
 
Figure 14: Saturation curves of different pulmonary surfactant materials by BDP. The capacity of different 
pulmonary surfactant lipid or lipid/protein suspensions to incorporate the corticosteroid has been assessed by 
plotting the amount of incorporated drug vs. the total amount of drug (drug/lipid weight ratio) at which the 
suspensions have been exposed. A) Saturation curves for NS, its organic extract and MLV and LUV pure lipid 
suspensions (DPPC/POPG, 7:3 w/w). B) Saturation curves for clinical surfactants Poractant alfa and CHF5633. 
Lines represent the best fit of experimental data to a hyperbolic saturation curve. 
Impact of corticosteroids on surfactant functional properties 
Once established that the drug interacts and is incorporated into surfactant complexes, the 
impact of the drug on the biophysical properties of surfactant to form and sustain surface active 
films under physiological constrains was analysed using the CBS. At 10% BDP/lipid ratio, most 
surfactant preparations were above its 80% saturation limit and, therefore, this amount of 
corticosteroid was selected to analyse the effects of the presence of the drug on the interfacial 
behaviour of the different surfactants. In Figure 15 the activity of NS and its reconstituted OE is 
analysed and compared in the absence and in the presence of 10% BDP. 
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Figure 15: Effect of BDP on the functional behaviour of NS and its organic extract, as assessed in the CBS. -
t interfacial adsorption kinetics are compared in the absence or presence of BDP, for suspensions of NS (above) 
and of its organic extract (below), during either initial (left) or post-expansion (center left) adsorption. Data are 
average and error bars the standard deviation upon averaging the results of three different experiments. 
Representative -A compression-expansion isotherms, obtained during slow quasi-static (center right) or rapid 
breathing-like dynamic (right) compression-expansion cycling are also compared in the presence or absence of 
the drug. In the graphs the four quasi-static (1st to 4th from left to right) and 1st, 10th, and 20th dynamic cycles are 
compared. 
Both, native surfactant and its organic extract showed very good initial and post-expansion 
interfacial adsorption that was not substantially affected by the presence of drug. This means that 
the presence of the corticosteroid into the surfactant complexes does not alter their ability to 
rapidly associate to the air-liquid interface, to transfer lipid surface active species to form an 
orientated surface film that reduces surface tension to equilibrium values around 22-24 mN/m 
(seen in initial adsorption kinetics), and to spread and replenish the interface from associated 
structures once it is expanded (assessed in post-expansion adsorption). The main differences 
introduced by the presence of BDP are observed at the quasi-static compression-expansion 
isotherms. In these experiments, compression-expansion cycles are applied to the bubble in 
discrete slow steps, intercalated by lapse periods of time during which the film can relax. The 
analysis of these isotherms allows getting information about the compressibility properties and 
the stability of the films, which can reorganize or experiment three-dimensional transitions usually 
detected by the presence of plateaus at the isotherms. These reorganizations or plateaus, typically 
observed in the first cycles, would be only partially detected under the kinetically limited conditions 
imposed by rapid compression-expansion cycles mimicking breathing dynamics. Q-static 
isotherms displayed in Figure 15 show how the presence of the corticosteroid induces the 
manifestation of plateaus into the compression legs, and, as a consequence, isotherms that 
require larger area reductions before the minimal tensions are reached. Frequently, several slow 
compression-expansion cycles are required before the isotherms of the films containing BDP are 
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stabilized to produce the lowest tensions with minimal area reduction (see Q-static isotherms of 
NS in the presence of BDP). The higher hysteresis of Q-static isotherms of NS and OE in the 
presence of BDP is likely associated with a compression-driven progressive exclusion of the drug 
from the interface, because the rapid dynamic compression-expansion cycles carried out 
afterwards produce non-hysteretic isotherms indistinguishable in the absence and presence of the 
drug. 
 
Figure 16: Effect of corticosteroids on the functional behaviour of Poractant alfa. Interfacial adsorption either 
upon initial injection at the surface of an air bubble at the CBS or upon bubble expansion has been compared 
for Poractant alfa alone (first row) or loaded with 10% (w/w with respect to phospholipid) BDP (2nd, 3rd and 5th 
rows) or BUD (4th and 6th rows) through different protocols. Plotted in the left panels are mean data with 
standard deviation after averaging three different adsorption experiments. Right panels show illustrative 
isotherms for cycles 1-4 under quasi-static and cycles 1, 10 and 20 under rapid dynamic compression-expansion 
regimes applied to the different films. 
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In Figure 16 the functional behaviour in the CBS of the clinical surfactant Poractant alfa is 
evaluated in the absence or presence of the corticosteroids BDP or BUD. The figure also compares 
the effect of the drugs incorporated by the different protocols. As observed in the adsorption and 
compression-expansion isotherms of NS and OE, the presence of any of the corticosteroid, 
incorporated by any of the tested protocols, minimally affected the performance of surface films 
formed by Poractant alfa once subjected to compression-expansion dynamics. Initial adsorption 
of Poractant alfa was slightly affected by the presence of BDP, particularly when the drug was 
premixed with the surfactant material in organic solutions, presumably because that maximizes 
the incorporation of the drug into deep regions of surfactant lipid-protein complexes. Initial 
adsorption was also somehow slightly slowed when BDP was incorporated into Poractant alfa as 
part of Clenil. This is likely a transient effect of Clenil excipients, as observed upon exposure of 
Poractant alfa to equivalent emulsions BDP-free Clenil excipients (see Figure 17). However, in all 
the experiments, and once the interface of the bubble was opened, post-expansion adsorption 
was equally rapid in the absence and in the presence of the drug, indicating that the inhibition 
mechanism is by competition for the interface, instead of altering the composition of any surfactant 
elements. 
 
Figure 17: Excipients and Clenil effects on initial adsorption of Poractant alpha and CHF5633. Clenil® and its 
excipients clearly adsorb into the air-liquid interfase and affect the interfacial adsorption of both Poractant alpha 
and CHF5633, likely due to an inhibition by competition for the interface. This effect is more accentuated when 
the excipients are injected before surfactant than a mixture of both and CHF5633 seems to be more susceptible. 
Each plot represents the mean data with standard deviation after averaging three different experiments. 
As illustrated in Figure 18, the reconstituted surfactant CHF5633 can also incorporate 10% 
by weight of BDP or BUD with respect to phospholipid without relevant impairment of its functional 
properties. Initial adsorption of CHF5633 alone often produces not very low surface tensions at 
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first instance. However, upon interfacial expansion, this surfactant almost instantaneously reduced 
surface tension to equilibrium tensions of aprox. 25 mN/m, indicating the ultimate efficient transfer 
of surface active lipids into the interface. CHF5633 films could then reduce surface tension further 
to very low values of around 2 mN/m upon repetitive compression-expansion cycling. Interestingly, 
corticosteroid-loaded CHF5633 samples exhibited improved interfacial adsorption from the initial 
contact with the air-water interface, likely as a consequence of the slight perturbation introduced 
by the incorporated drugs on membrane fluidity. Neither BDP nor BUD altered substantially 
compression-expansion isotherms of CHF5633 films, as observed in the quasi-static or dynamic 
-A isotherms in Figure 18. 
 
Figure 18: Effect of corticosteroids on the functional behaviour of CHF5633. Interfacial adsorption either upon 
initial injection at the surface of an air bubble at the CBS or upon bubble expansion has been compared for 
CHF5633 alone (first row) or loaded with BDP (2nd row) or BUD (3rd, 4th and 5th rows) through different protocols. 
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Plotted in the left panels are mean data with standard deviation after averaging three different adsorption 
experiments. Right panels show illustrative isotherms for cycles 1-4 under quasi-static and cycles 1, 10 and 20 
under rapid dynamic compression-expansion regimes applied to the different films. The amount of drug in the 
different experiments was 10% (w/w with respect to phospholipids) except for BUD incorporated from 
Pulmicort, whose proportion was 1%, the maximal amount allowed by the dilution of CHF5633 with Pulmicort 
to reach the operational surfactant concentration. 
Interfacial vehiculization of corticosteroids 
To assess whether incorporation into surfactant allows an efficient transfer and spreading 
of the drugs, we used a novel custom-made experimental design. As described in the 
Vehiculization troughs section, two different troughs (donor and recipient) were connected, each 
monitored by a surface pressure sensor, by an interfacial bridge. PS samples, in the presence or 
in the absence of the drug, were introduced into the donor trough, and following the changes in 
surface pressure in both troughs we could monitor adsorption and movement of any surfactant 
material through the air-liquid interface.  
Figure 19 summarizes the adsorption/spreading isotherms of different materials from the 
donor trough, where they were originally introduced, to reach the recipient compartment via 
diffusion through the air-liquid interface. 
CHAPTER I: The proof of concept 
 
69 
 
 
Figure 19: Pulmonary surfactant-assisted interfacial vehiculization of corticosteroids. Compared are 
adsorption/spreading isotherms of Poractant alfa (first row) and CHF5633 (second row) in the absence (left 
panels) or presence (central panels) of BDP/BANB (9% total drug/phospholipid, 1% fluorescent probe), as 
measured by the increase in surface pressure detected in the donor (black line) or in the recipient (grey line) 
trough of a setup such as the one illustrated in the upper cartoon. At the time indicated by the arrow, interfacial 
material was harvested by suction at the surface of the recipient trough and further changes with time of surface 
pressure were continuously followed as additional material was diffusing again from the donor trough. Data 
represent mean and standard deviation after averaging three different experiments. Compared are also 
adsorption/spreading isotherms of BDP/BANB Clenil (3rd row), or of a sample of DPPC/POPG (7:3, w/w) LUV 
liposomes (4th row) in the absence or presence of 10% BDP/BANB. On the right, the fluorescence emission 
spectra are compared of samples taken from the recipient trough at the end of the experiments. 
When an aliquot of any of the two clinical surfactants tested, Poractant alfa or CHF5633, 
was deposited at the donor trough, an immediate increase of surface pressure up to around 35-
38 mN/m was recorded. After a lag time of aprox. 5-7 min, surface pressure started to increase 
also at the recipient trough, once the material adsorbed into the air-water interface of the donor 
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chamber diffused along the interfacial connecting bridge. The increase in pressure in the recipient 
trough was accompanied by a slight decay in pressure at the donor chamber, indicating the 
transfer of material between the two compartments. However, surface pressure at the donor 
trough never dropped below 30 mN/m, indicating that transfer of material towards the recipient 
chamber was associated with a continuous adsorption and replenishment of further material from 
the donor subphase. At a given time during the experiment (indicated by an arrow in the panels 
of Figure 9), the interfacial material at the recipient trough was cleared by aspiration, which 
produced an immediate decay in surface pressure. However, this decay was rapid and 
subsequently compensated by new adsorption and transference from the donor trough. This -t 
kinetics demonstrated that there is a rapid and continuous connection of the two chambers via 
the air-liquid interface, and that this interfacial space can be used for a rapid interface-driven 
spreading and diffusion of surfactant material.  The interfacial transfer of material between the two 
troughs could be followed in a comparable way when either Poractant alfa or CHF5633 were 
introduced in the donor trough. Interfacial transfer kinetics of these two materials were not affected 
when either of the two clinical surfactants were preloaded with 10% of BDP (with 1 % (w/w) 
consisting of the fluorescent analogue BANB), confirming that the inclusion of the corticosteroids 
did not alter the ability of the surfactants to adsorb and spread along the interface. Interestingly, 
when the material spread at the interface of the recipient trough was collected and taken to the 
spectrofluorometer, the fluorescence spectrum of the probe could be easily detected (see right 
panels in Figure 9), indicating that the drug had diffused from the donor to the recipient chambers 
following the surfactant. The lower panels in Figure 9 illustrate how the introduction in the donor 
trough of a pure lipid sample (DPPC/POPG 7:3 w/w liposomes) produced a marginal increase in 
pressure, as a consequence of a poor adsorption of the lipids in the absence of any surfactant 
protein. The incorporation of BDP into those liposomes did not produce any improvement in 
interfacial adsorption and, as a consequence, very limited diffusion of material from the donor to 
the recipient trough. Therefore, we could not detect the fluorescence of BANB originally 
incorporated into the liposomes once material from the interfacial recipient compartment was 
extracted. Similarly, BANB was not transferred from the donor into the recipient chamber when 
the drug was introduced as a solution in Clenil excipients, the typical formulation in which BDP is 
administered to patients. 
DISCUSSION 
Several studies have reported the benefits of administering clinical steroids in combination 
with PS 120, 122, 171. However, until now the ability of different surfactant formulations to incorporate 
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them, the potential impact of the drugs on PS function and its vehiculization capabilities along the 
air-liquid interface have not been investigated in detail. The data presented here support the 
concept that, provided a proper incorporation, PS is able to efficiently transport corticosteroids to 
long distances using the interface as a ‘shuttle’, without losing their ability to produce and sustain 
very low surface tensions along breathing-like compression-expansion dynamics. 
Surfactant formulations seem very efficient in solubilizing poorly soluble drugs such as 
corticosteroids. In fact, all the surfactant preparations tested here have shown affinity to 
incorporate drugs such as BDP or BUD, regardless of the way the drugs were presented to the 
surfactant complexes. Both natural and clinical surfactants induced favourable partition of 
corticosteroids from dry films at the walls of glass tubes into their phospholipid-based membranes, 
and incorporating the drugs from their clinical formulations like Clenil or Pulmicort, typically used 
to deliver inhaled corticoids. We presume that corticosteroid molecules, somehow similar to 
cholesterol, a natural component of pulmonary surfactant in most species, likely integrate into 
phospholipid surfactant membranes simulating the way how cholesterol distributes between 
liquid-disordered and liquid-ordered regions 172, 173. Pulmonary surfactant composition and 
structures are prepared to accept a certain proportion of steroids, at least up to ca. 15-20% (by 
weight with respect to phospholipids), without any impairment in surfactant function, as it has 
been demonstrated in the past 174, 175, 176. Our drug incorporation experiments determined that 
both natural surfactant and clinical surfactants like Poractant alfa or CHF5633 can readily 
incorporate up to 10% by weight of corticosteroids, constituting a very efficient potential vehicle 
to convert the drugs into a deliverable formulation. Porcine natural surfactant already contains 
around 5-8% of cholesterol 42, while Poractant alfa and CHF5633 are produced in the absence 
of cholesterol. Taking into account that we are incorporating around 10% of additional steroid, 
none of the tested surfactant loadings goes beyond the potentially deleterious ratio of 20% steroid 
174.  
Detailed functional analysis in the captive bubble surfactometer, under conditions simulating 
the demanding conditions imposed by respiratory mechanics, confirm that corticosteroid 
incorporation does not alter the main properties of porcine natural surfactant or those of the 
clinical preparations, Poractant alfa and CHF5633. The three pulmonary surfactant preparations 
tested exhibit good interfacial adsorption, both upon initial contact with the air-liquid interface or 
upon expansion of an interface previously exposed to the surfactants, once loaded with the drugs. 
The synthetic surfactant CHF5633 even shows better initial adsorptive properties in the presence 
of BDP or BUD than in their absence. We think that this is consistent with a fluidifying effect of 
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the drug on the surfactant membranes, in a similar manner to what could be caused by a small 
percentage of cholesterol, thus promoting a more dynamic behaviour to interact and transfer 
surface active phospholipid molecules from the beginning, even before such dynamic transfer 
could be induced by an expanding interface. The main difference in the surface behaviour of 
corticosteroid-loaded surfactants compared with the corresponding drug-free preparations can be 
observed at the quasi-static compression expansion isotherms. In these experiments, a very slow 
compression can allow the reorganization of surfactant films to rearrange the distribution of the 
components that are less stable at the highest compressions, when the films are forced to adopt 
very high molecular packing. It seems that surfactant films, particularly those formed by the native 
surfactant, undergo a more extensive compression-driven reorganization in the presence of drugs, 
as noticed from the frequent larger plateaus, inducing an expansion of the q-static isotherms to 
large compression rates. For instance, NS films require 40-45% area reduction during the first q-
static compression to reach minimal surface tension, whilst they reach a similar minimal tension 
with less than 20% area reduction in the second compression cycle. In contrast, and once loaded 
with 10% BDP, NS films require >50% area reduction to reach minimal tension in the first Q-
static cycle, 40% in the second, and 25% in the third one. Only after four slow compression-
expansion cycles the film is competent to produce minimal surface tension with less than 20% 
area reduction (see Figure 15). The increase in the hysteretic behaviour of NS films cycled at slow 
speed when the surfactant is bearing the corticosteroid could be interpreted as a consequence of 
the larger area reduction required during compression to produce the squeeze-out of the drug to 
surface-associated compartments that are likely out from the interface, and therefore do not 
interfere with reaching the maximal packing required to produce minimal tension at the end of 
compression. The drug could then be excluded from the interface in a similar manner to some of 
the natural surfactant components, such as unsaturated lipids or cholesterol 4, 177. A similar 
behaviour has been also reported for NS films incorporating cholesterol or other spurious 
components such as those from meconium 177, 178, 179. Interestingly, none of the clinical 
surfactantstested, Poractant alfa or CHF5633 do not show so marked increase in hysteresis as 
observed in the q-static isotherms of NS films. We think that this difference could be due to the 
different intrinsic content of cholesterol. The larger exclusion plateaus in NS isotherms could be a 
consequence of a proportion of steroid near to the limit accepted by films compressed at tight 
packing 180. Clinical surfactants films, with no cholesterol, could still accept 10% of corticosteroid 
at their maximal pressures (minimal tensions). 
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The innocuous effect of corticosteroids such as BDP or BUD on the dynamic surface 
properties of PS complexes open new opportunities to use corticosteroid-loaded clinical 
surfactants as a basis of inhalable delivery strategies. Our double trough experiments demonstrate 
that corticosteroid-loaded surfactants can take the drug with them to adsorb onto peri-interfacial 
compartments, promoting its vehiculization to long distances through diffusion along the air-liquid 
interface. Surfactant could then be prepared to use the interface as a ‘shuttle’ to spread the drugs. 
This might change, the potentially exploitable concept of inhalable strategies intended to deliver 
drugs through the paediatric or neonatal airways 4. Traditional drug delivery through the airways 
has been usually linked to the production of small enough vehiculizable entities, such as 
aerosolized or nebulized particles of less than 2 µm of diameter 181. According to that idea, only 
the smallest particles, propelled with enough energy, could be able to reach the narrowest distal 
airways and the alveoli. This could be particularly important for drugs intended for a lung-mediated 
systemic delivery, because the alveolar-capillary barrier is the surface exhibiting more favourable 
transport capabilities. However, we show here that if drugs are properly integrated into a clinical 
PS, in the right amounts and using procedures that preserve the most favourable surfactant 
dynamic properties, drugs could readily adsorb into the air-liquid interface and along it, travel from 
the upper to the distal airways to efficiently spread along the whole lung.
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INTRODUCTION 
Most studies analysing the interactions of different exogenous compounds with the 
respiratory system have been mainly focused on their potential toxicological effect on the lung 
epithelium. Few reports have included pulmonary surfactant as an important element that could 
be targeted in this regard and even less considering it as a drug delivery system. However, the 
consideration of this essential system as a key element in respiratory drug delivery is increasing 
in the recent years. Indeed, a deep understanding of how drugs or nanoparticles may affect the 
structure and surface behaviour of pulmonary surfactant is essential to optimize the design and 
production of improved drug delivery strategies targeting the airways, not only to avoid 
toxicological effects but also to get synergistic effects from their combination. 
As aforementioned, pulmonary surfactant is secreted into the alveolar spaces where it 
accomplishes its main function: reducing the surface tension of the layer of water covering the 
whole respiratory surface. The lungs are continuously inflating and deflating during the process of 
breathing, a phenomenon that makes alveoli to be uninterruptedly dilating and contracting. This 
highly dynamic process is translated into a subsequent compression and expansion of the 
interface between that layer of water and the breathing air. As pulmonary surfactant is located as 
a film in this dynamic air-water interface, it has been optimized to adapt to such active 
environment, producing surface tensions below 2 mN/m (surface pressures above 70 mN/m). 
The ‘squeeze-out’ model is widely accepted to explain some of the transformations suffered by 
the surfactant films subjected to compression. It states that the interfacial film folds down to form 
3D multi-layered structures enriched with unsaturated phospholipids, leaving the interface 
accumulating most of  DPPC. This mechanism allows surfactant films to form compression-driven 
transient metastable structures, excluding material that cannot be packed enough to sustain the 
minimal tensions, below 1–2 mN/m 65. These 3D structures maintain stable the association with 
the interface presumably thanks to proteins SP-C and SP-B. Moreover, they can reinsert into the 
interface during expansion, ensuring the integrity of the film along successive breathing cycles 47. 
Since Dr. Irving Langmuir 182, 183 and Dr. Katherine Blodgett improved the device developed 
by the German and ‘independent-for-obligation’ scientist Agnes Pockels to study the behaviour of 
oils in air-water interfaces, many surface active components have been tested. However, it was 
not until 1957 when Dr. John Allen Clements proposed the Langmuir and Blodgett method to 
study the interfacial behaviour of pulmonary surfactants. The possibility of studying this system 
under compression and expansion conditions, modelling somehow the alveolar dynamics, makes 
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the Langmuir-Blodgett trough the most extensive technique to study the structural insights of 
pulmonary surfactant and the effects that different compounds could have on it. 
Particularly in this chapter, an improvement of this technique is proposed to study the 
interfacial behaviour of hydrophobic drugs, focusing on the structural effects that they could 
produce on pulmonary surfactants films. This novel setup allows to highlight the importance of 
interfacial dynamics to enhance both drug delivery and its subsequent release from the air-liquid 
interface. Proper surfactants and simpler models consisting of lipid-protein mixtures or pure lipids 
can be used to perform experiments and better understand the role of each lipid-protein 
component. In particular, DPPC (the simplest model), purified porcine surfactants (emulating 
endogenous surfactant) and their organic fraction (mimicking clinical/exogenous surfactants) 
were assessed in combination with tacrolimus (TAC, FK-506 o Fujimycin). This compound is an 
immunosuppressive drug widely used during lung transplantation that can be considered as a 
good model for testing hydrophobic drugs.  
This chapter pretends to explore from a structural and dynamic perspective how the drug 
travels over the interface and is released once in the desired location and the role of interfacial 
dynamics in the vehiculization and release processes. 
KEY TECHNIQUE 
Langmuir-Blodgett trough 
The Langmuir-Blodgett trough allows for study the interfacial behaviour and the structural 
transformations of surface active materials in the presence or the absence of additional 
compounds, under dynamic conditions of compression and expansion. It consists of a 
thermostated Teflon trough filled with liquid (a water solution, generally), a surface pressure 
sensor, a transference system (dipper) and a barrier able to compress and expand the molecules 
confined at the air-liquid interface (see Figure 20). When the sample is applied on the interface 
(either in aqueous or organic solution), amphipathic molecules such as phospholipids spread 
along it forming a confined interfacial monolayer, also known as Langmuir film. Although there are 
several designs for the barriers, the barrier at the Langmuir-Blodgett trough used in this Thesis is 
a Teflon ribbon partially immersed into the aqueous subphase (purchased from NIMA 
technologies, Coventry, UK). This barrier is fixed forming an area-variable rectangle (from 185 
cm2 to 58 cm2) with own-designed cylindrical pieces at vertexes that avoid the leakage of 
interfacial material at high compression rates. 
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Figure 20: Langmuir-Blodgett trough. A) Images of characteristic parts of the Langmuir-Blodgett trough. B) 
Schematic representation. 
When the barrier closes, the film is compressed and the phospholipids rearrange laterally in 
the interface, increasing the lateral pressure and reducing the area per molecule. After this, the 
barrier can be opened to study how the interfacial molecules behave during expansion. 
Additionally, it can also be repeatedly opened and closed to observe the effects of this dynamism 
on the films. The changes in surface pressure (π) are constantly monitored by a pressure sensor 
that transduces the signal to a computer. When the area per molecule is so low that promotes 
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intermolecular interactions, the surface pressure start to rise. These changes in surface pressure 
are usually represented with π-area isotherms and reflect how interfacial molecules are organised 
into the air-liquid interface. Low pressures indicate that molecules are completely dispersed along 
the interface, while high pressures are usually associated with highly ordered states characterized 
by tightly packed lipids at the air-liquid interface. At maximal compression, those molecules which 
cannot support such pressures are excluded from 2D to 3D planes (see Figure 21). 
 
Figure 21: π-area isotherm of a DPPC film at 25 °C with the associated interfacial lipid phases. Taking the 
isotherm of DPPC as a model, five different packing states (lipid phases can be described). The gas phase (G) at 
low surface pressures, where phospholipids are dispersed along the interface and can move freely. Then liquid-
expanded (Le), where they occupy less area per molecule but still have free motion. Lipids start contacting each 
other and surface pressure rises. At the liquid-condensed (Lc) phase, where the acyl chains are orientated 
perpendicular to the interface and the molecules are tightly packed. The plateau at around 12 mN/m in DPPC 
represents a coexistence between Le and Lc phases, where the work of compression is applied to achieve the 
ordered lateral packing of the interfacial molecules. If the lateral pressure is higher than the threshold that they 
cannot resist, the molecules are excluded out from the interface (collapse or C). 
The presence of additional molecules intercalated between phospholipids can produce 
changes in the area occupied per molecule, the compressibility of the layer and the cooperativity, 
or modify completely how phospholipids organise into the interface. This can easily be detected 
by variations in the shape of the isotherm. Hence, this technique is very useful to study interfacial 
properties of pulmonary surfactant and how incorporated elements such as drugs, nanocarriers 
or pollutants interact with it. The possibility of compressing and expanding the interface also 
permits to evaluate whether this dynamism, analogous to that occuring in alveoli during breathing, 
enhances the depuration or release of those additional molecules from the interface. 
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Apart from evaluating the changes in surface pressure, the interfacial films can also be 
transferred onto solid supports to observe in detail their structure under a microscope (i.e. 
epifluorescence or AFM, as it is the case of this Thesis). The transference could be performed at 
constant pressure, where the barrier is automatically moved to compensate for the pressure 
reduction due to material loss during the transference. Alternatively, transference can be 
performed at continuously varying surface pressure (COVASP), where the film is transferred while 
closing the barrier to have the film at all possible pressures into the same sample 184, 185. As shown 
in Figure 22, the methodology changes depending on the properties of the support, determining 
the orientation of the lipids in the transferred film. 
 
Figure 22: Protocol to transfer monolayers onto hydrophobic or hydrophilic supports, to form Langmuir-
Blodgett films. 
In this Thesis, all the supports used to transfer the interfacial films were hydrophilic: glass 
for epifluorescence microscopy and mica for AFM. As AFM allows to scan the surface of samples, 
it is possible to observe different heights in interfacial films and analyse their 3D organization 
under compression-expansion dynamics. These different heights usually correspond to clusters of 
phospholipids (lipid domains) with different packing stages (lipid phases) or several layers of 
them (3D structures), as the height of phospholipid acyl chains increases during the packing of 
lipids upon compression. For epifluorescence analysis, samples have to be labelled with 
fluorescent dyes prior to their deposit onto the Langmuir-Blodgett trough. These probes are 
normally fluorescent molecules covalently attached to phospholipids (head or acyl chains). Thus, 
depending on the size and the position of the fluorescent group and the saturated or unsaturated 
nature of its acyl chains, such dyes can be employed to label packed domains or fluid phases. 
Having this in mind, it is possible to observe and described the lateral distribution of interfacial 
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molecules. When labelled phospholipid cannot support highly packaged status, as it is the case of 
the NBD-PC used in this Thesis, it will be excluded from the most condensed domains upon 
compression. This leads to detect the ordered phase as dark structures with growing sizes as the 
lateral pressure increases. 
Looking at the possibilities of this technique, together with the vehiculizing trough 
developed in this project, we decided to go further and connect both the traditional Wilhelmy and 
Langmuir-Blodgett trough through interfacial bridges (see Figure 23). The former is still the donor, 
while the latter acts as the recipient. This novel dynamic in vitro model of the respiratory surface 
opens new possibilities to understand how surfactant and its passengers behave interfacially under 
compression and expansion conditions. The larger recipient surface also helps to collect more 
molecules improving the detection. The possibility of removing the interfacial bridge after travelling 
or cycling also increases the potential of this technique. Specifically, removing the bridge just 
before performing compression-expansion cycles, supposes an unprecedented strategy. The 
surfactant film that has already spread can be carefully analysed, avoiding the adsorption of new 
material coming from the surfactant reservoir in the subphase. When the cycles are performed in 
the presence of the bridge, it is possible to analyse how cycling enhances the surfactant trip along 
the interface. Additionally, the experiment can be continued beyond the dynamic cycles to evaluate 
the readsorption of interfacial-associated membranes (removing the bridge and monitoring the 
surface pressure for a certain period of time) or to check whether successive interfacial 
compression-expansion cycles favour the interfacial reposition of new material coming from the 
donor reservoir (leaving the bridge and monitoring the surface pressure for some additional time). 
 
Figure 23: Schematic representation of the dynamic vehiculization trough. 
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RESULTS 
Traditional models in a classical technique: Exploring how a hydrophobic drug 
interacts with pulmonary surfactant and behaves interfacially 
DPPP monolayers and hydrophobic drugs: the simplest model of pulmonary surfactant 
to study interfacial distribution 
To study how hydrophobic drugs are distributed laterally in interfacial monolayers of DPPC 
and to elucidate how they could interact with pulmonary surfactant, three different proportions 
(1%, 5% and 10% w/w with respect to DPPC) of Tacrolimus have been assessed. Each 
DPPC/drug combination, dissolved in Chloroform/Methanol (2:1 v/v), was directly distributed into 
the air-liquid interface to form a simple monolayer. After 10 minutes, waiting for organic solvents 
to evaporate, the compression isotherm (barrier speed: 25 cm2/min) for each Tacrolimus 
proportion was obtained while transferring the monolayers to a glass plate (deeper speed: 5 
mm/min). As shown in Figure 24, the crescent addition of TAC alters the lateral structure of DPPC 
impeding the formation of compression-driven domains. At lower surface pressures, the area per 
molecule of phospholipid increases upon the addition of TAC, indicating that the drug actually 
intercalates between DPPC molecules at the interfase. At a surface pressure of around 10-12 
mN/m and a temperature of 25 °C, when DPPC begins to undergo a lateral reorganization with 
its resulting characteristic plateau in the isotherm, the size of both micro- and nano-domains is 
clearly reduced (observed by epifluorescence microscopy and AFM). The formers are not even 
formed when the highest amount of TAC is assessed. This effect is also possible to observe 
looking at the isotherms, where the plateau is shifted among the increasing amounts of TAC. 
These effects may indicate that tacrolimus is interacting with DPPC molecules and obstructing 
their lateral reorganization in the interface. At pressures higher than the exclusion surface pressure 
of TAC in DPPC monolayers (around 30 mN/m), the isotherms remain similar suggesting that 
tacrolimus is being excluded from the interface at a level that does not affect the DPPC behaviour. 
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Figure 24: Effect of increasing amounts of tacrolimus on DPPC interfacial monolayers. The graph represents 
the transference isotherms of DPPC at 25 °C in the presence of increasing amounts of TAC (1%, 5% and 10% by 
mass with respect to DPPC). Samples were spread over the surface disolved in Clorodorm/MetOH (2:1 v/v). After 
10 min, the barrier was closed at 25 cm2/min and the deeper 5 mm/min to ensure a proper transference of the 
monolayers. The plateau observed at around 12 mN/m corresponds to the coexistance of two differentes lipid 
phases (liquid expanded (Le) and liquid condensed (Lc)). Epifluorescence images show the lateral distribution of 
DPPC and how the growing addition of TAC alters the formation of macro-domains of highly packed DPPC (Lc; 
black regions); the green color corresponds to Le where phosphatidylcoline labelled with the fluorescent probe 
nitrobenzoxadiazole (NBD) is located as a consequence of its lateral exclusion from the high ordered domains at 
high levels of packing. Atomic force microscopy (AFM) images represents how TAC affects the lateral 
arrangement of DPPC molecules in nano-domains. Bars: Epifluorescence = 50 µm; AFM = 8 µm. 
In order to track where TAC localises along the air-liquid interface in the presence of DPPC 
and its interfacial behaviour during compression, the same experiments were performed using a 
fluorescent tacrolimus labelled with NileBlue (TAC·NileBlue). Only the 1% by mass of TAC·NileBlue 
were added as a trace; the rest amount to complete the three assessed proportions was intact 
TAC to minimize the possible additional effect of the dye. As shown in Figure 25, the size of domains 
was different depending on the filter used to observe the fluorescence of NBD-PC or TAC·NileBlue 
under the epifluorescence microscope. Particularly, the domains observed with the NBD-PC filter 
were consistently smaller than the same detected by the TAC·NileBlue one. However, these 
differences decrease upon compression, suggesting that the lateral exclusion is a gradual process 
where the drug molecules are laterally excluded at lower surface pressures than NBD-PC. Figure 
25B also shows how at the highest TAC·NileBlue concentration the effect of altering the lateral 
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phase transition is taking place at higher surface pressures, indicating that TAC is broadening the 
phase transition of DPPC even until pressures near to the exclusion of TAC, as it is also observable 
in Figure 24. 
 
Figure 25: Lateral exclusion of TAC from highly packed DPPC domains. A) The same domains seen under 
different filters (representative colours; green: NBD-PC; red: TAC·NileBlue). White arrows indicate the strategy 
used to measure their difference in size. Bar = 10 µm. 
Figure 26 represents the distribution of the total amount of pixels along the 256 levels of 
grey from row images taken by the epifluorescence microscope to continuous-pressure 
transferences. Interestingly, the images corresponding to TAC·NileBlue show a progressive 
displacement of the whole pixels to the darker levels upon compression. This shifting can be 
traduced into a reduction of intensity derived from fluorescence loss. Considering that all samples 
were handled equally and images were taken maintaining the same exposure times (200ms) at 
higher lamp intensity, it can be supposed that this loss of fluorescence may be associated to an 
exclusion of fluorescent molecules from the interface. Regardless the amount of TAC, at surface 
pressures below the plateau, the pixels were accumulated in slightly darker levels than the same 
observed just at the beginning of the plateau, suggesting that molecules at the interface are 
somehow laterally clustering, resulting in brighter images. Although this clustering is more evident 
at pressures above the plateau due to the presence of bigger domains, all the pixels are 
concentrated in considerable darker levels, suggesting that TAC could not only be excluded 
laterally but also interfacially during compression. 
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Figure 26: Representative histograms of images showing how TAC () is excluded from the air-liquid interface 
over compression. Each histogram corresponds to one of the images below at the indicated lateral pressure. 
Raw images. Bar = 50 µm. 
To further explore the potential interfacial depuration, the monolayers were subjected to five 
compression and expansion cycles. Figure 27 shows that after cycles the effect of TAC is apparently 
reverted. When the sample is mixed with TAC at 10% w/w, it is evident that DPPC starts 
generating domains at higher pressures than pure DPPC. However, after five compression-
expansion cycles, this effect is partially reverted and DPPC forms domains. 
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Figure 27: Epifluorescence images showing how compression-expansion cycles promote the interfacial 
exclusion of TAC. Representative images taken before and after five compression-expansion cycles at the 
pressures indicated on each image. Representative colours; green: NBD-PC; red: TAC·NileBlue. The histogram of 
each image was adjusted to better differentiate the structures in the image (fluorescence of each dye after cycles 
was reduced as a consequence of interfacial exclusion). Bar = 50 µm. 
In Figure 28 the release process during the compression-expansion cycles is represented. 
The isotherms clearly show how the area per molecule, especially with the maximum amount of 
TAC, is decreasing over the cycles. This reduction of area at the lowest pressures indicates that 
the monolayer is likely losing material (DPPC, TAC or both) from the interface during interfacial 
dynamics. When focusing on the plateau, the same process can be observed as a progressive 
shifting to the left. Once again, looking at the shape of the whole isotherms after the cycles, they 
resemble pure DPPC. These results indicate that the monolayer could be mainly losing TAC, 
confirming that TAC is not only excluded laterally but also three-dimensionally from the interface 
towards the aqueous subphase upon high pressures. 
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Figure 28: Interfacial exclusion process in DPPC monolayers. π-area isotherms of DPPC in the presence of 
crescent amounts of TAC (1% and 10% w/w) before, during and after five compression-expansion cycles. The 
zoom-like graph in the middle represents the reduction of area per molecule at 15 mN/m, which corresponds to 
the amount of material released over the cycles. 
Dissecting the interfacial exclusion from surfactant monolayers 
As mentioned above, TAC was able to colocalise with the liquid-expanded phase of  DPPC 
at the air-liquid interface and the interfacial dynamics promotes its exclusion from there. Hence, 
the next step was to test whether a similar behaviour occurs in combination with pulmonary 
surfactants. In this case, the organic fraction (OE) of a self-purified porcine surfactant was 
combined with the TAC proportions used in the previous experiments with DPPC (1%, 5% and 
10% w/w). Each OE/drug combination, dissolved in Chloroform/Methanol (2:1 v/v), was directly 
distributed into the air-liquid interface of the Langmuir-Blodgett trough. Then, the compression 
isotherms and interfacial transferences were obtained before and after five compression-
expansion cycles. Figure 29 shows the isotherms before, during and after the dynamic process, 
revealing how the surfactant located at the interface is subjected to depuration during cycling. 
Specifically, before the cycles, it is clear that crescent amounts of TAC reduce the characteristic 
plateau of surfactant at around 40-45 mN/m. The slope upon compression is also reduced at 
lower pressures, meaning that the same area compression produces lower increase of pressure 
reducing the cooperativity. This induces to think that TAC is intercalating between surfactant 
elements and could somehow promote the exclusion of additional surfactant components at the 
same time of its exclusion upon compression. During cycles, a major reduction of area to reach 
the same surface pressure can be observed as TAC proportion is increasing. This is evident 
especially at lower pressures when it is expected to be excluded. Although this area is gradually 
reduced during cycles, this reduction is more evident upon the first compression. Moreover, after 
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the dynamic process, the surface pressure at the maximum surface area is considerably less than 
before. It may suggest that interfacial dynamics induces liberation of some surfactant components 
and enhances TAC release from the interface. 
 
Figure 29: Interfacial exclusion process in surfactant monolayers. π-area isotherms of surfactant in the presence 
of crescent amounts of TAC (1% and 10% w/w) before, during and after five compression-expansion cycles. The 
zoom-like graph in the middle represents the reduction of area per molecule at 15 mN/m, which corresponds to 
the relative amount of material released over the cycles. 
In an attempt to characterise this process graphically, Figure 30 shows a representative image 
of a surfactant monolayer containing 5% of TAC at a surface pressure near the end of the plateau 
(47.5 mN/m). In this image, which is a merge between the filter using to detect the fluorescence 
of NBD-PC and TAC·NileBlue, different regions can be observed. The darker area that mainly 
covers the whole image corresponds to surfactant clusters from where both fluorescent dyes have 
been laterally excluded. Then, a green brighter crack containing some yellow circular structures 
that remains to vesicles can be observed. Knowing that NBD-PC is represented in green and 
TAC·NileBlue in red it is possible to interpret that those vesicle-like structures are composed by 
both NBD-PC and TAC·NileBlue. This could demonstrate that during compression there is a 
rearrangement of surfactant components and the drug, which generates different clusters. These 
can be later squeezed-out from the interface in the form of vesicles-like arrangements at certain 
surface pressures that cannot resist at high pressure states. 
CHAPTER II: A structural trip through a dynamic interface 
89 
 
 
Figure 30: Squeezing out of TAC·NileBlue and NBD-PC. The images show an interface saturated with the organic 
fraction of a self-purified surfactant corresponding to pressures at the end of the plateau. The majority of the 
interface is covered by dark regions from where both dyes have been laterally excluded. They correspond to 
condensed phases, likely enriched with DPPC. White arrows indicate vesicles-like structures full of TAC·NileBlue 
and NBD-PC already excluded from the interface. The histogram of each images was firstly shortened and then 
contrasted to better differentiate the structures in the images. Merge is shown (Red: TAC·NileBlue; Green: NBD-
PC). Bar = 25 µm 
Dynamic vehiculization 
Setting up 
As observed in the previous experiments, pulmonary surfactant can incorporate TAC into its 
membranes with no significant effects on its functionality (see Figure S… in supplementary). 
Knowing that interfacial dynamics could also define the behaviour and destiny of the drug, the 
dynamic vehiculization of additional passengers was studied kinetically and structurally. As 
mentioned above, to perform these experiments, the double trough used in the Chapter I was 
modified.  Instead of being a static system, the substitution of the recipient trough by a Langmuir-
Blodgett trough allows to convert this respiratory surface model into a dynamic system. This 
change permits to better simulate the alveolar dynamism and evaluate the vehiculization 
capabilities of pulmonary surfactant considering additional parameters as never before. 
Before starting the experiments, the dynamic vehiculization trough was tested to ensure 
that instrumental variability would not affect the experiments. The adsorption and spreading 
capabilities were parallelly tested in both static and dynamic vehiculization troughs to confirm that 
both were able to produce similar results. A sample of the organic fraction obtained from purified 
porcine surfactant (15 µL at 50 mg/mL) was spread into both donor troughs in the form of an 
aqueous suspension. In Figure 31, which compares the changes in surface pressure over time in 
both donor and recipient troughs, no substantial differences were observed. When the aliquot of 
surfactant was added at either donor troughs, the same immediate increase of surface pressure 
up to around 41-42 mN/m was recorded (surfactant πeq). Once the material adsorbed into both 
donor air-water interfaces, it diffused equally along the interfacial connecting bridge. The lag time 
for surface pressure to start raising at the recipient trough was slightly superior in the dynamic 
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system due to the bigger surface area. However, this time difference did not impede to reach the 
maximum surface pressure at the same time (after 25 min). These results guaranteed that the 
experiments performed with the new set up were totally reproducible and no other instrumental 
variability more than the lag time affected them. 
 
Figure 31:  π-time inotherms measured in both static (left) and dynamic (right) vehiculization troughs. 
Adsorption and spreading capabilities of pulmonary surfactant have been analysed to evaluate instrumental 
variability between both vehiculization troughs. 
Interfacial dynamics promotes TAC release 
The previous experiments confirmed the ability of surfactant to transport drugs through an 
air-liquid interface. The next step was to determine how these drugs are released from the 
interface to play its therapeutic effect and whether dynamic cycles enhance this process after 
travelling interfacially. To demonstrate it, an aqueous aliquot (15 µL at 50 mg/mL) of OE in 
combination with 10% TAC (8% TAC + 2% TAC·NileBlue by mass) was deposited in the donor 
trough and subjected to 10 compression-expansion cycles in the recipient. These cycles were 
performed in the presence and in the absence of an interfacial bridge, maintaining both interfaces 
connected or disconnected, respectively. These strategies allow to study a) release of TAC over 
the cycles avoiding the possible material coming from the donor trough (with no bridge) and b) 
whether dynamics promotes the interfacial trip (with bridge). 
The π-time and π-area isotherms represented in Figure 32 illustrate several differences when 
the cycles are performed with donor and recipient interfaces either connected or disconnected. 
The continuous fluctuations observed in the donor isotherm (blue) during the cycles in the 
presence of the bridge (Figure 32 B) evidences that both interfaces are continuously connected. 
Therefore, every change in the interfacial film of the recipient trough is being transmitted to the 
donor via air-liquid interface. In the π-area isotherms, a progressive reduction of the characteristic 
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plateau of pulmonary surfactant at around 40-45 mN/m is observed in both situations. After this 
plateau, compressibility also decreases over the cycles, meaning that the interfacial film is 
progressively depurated from those components that cannot support such pressures, likely 
enriching the layer with DPPC. The major reduction of this plateau is observed during the first 
compression, regardless of the connection of both interfaces. Then, this reduction is more gradual, 
suggesting that the main depuration occurs at this moment. Upon removing the interfacial bridge 
before cycling (Figure 32A), the maximum pressure slightly decreases over the cycles, compared 
to the situation when both interfaces are connected. In the case of the minimum pressures, this 
difference is more accentuated, confirming that the material lost during the compression is not 
replenished during the expansion. When both interfaces are connected, this decrease in lateral 
pressure is not that obvious after the subsequent expansions, though during the first cycle is 
similar. 
 
Figure 32: π-time and π-area isotherms showing that compression-expansion dynamics promotes the 
interfacial trip. A) Removing the interfacial bridge just before the cycles (disconnected). B) Leaving the bridge 
during the whole experiment (connected). 
Comparing the isotherms during the first and last compression with pure DPPC (Figure 33), 
it is clear that surfactant films only resemble DPPC behaviour after the exclusion plateau, when 
surface pressure can reach values close to 72 mN/m (only feasible by DPPC monolayers). After 
dynamic cycles, the isotherms show more reduced plateaus allowing surfactant films for reaching 
these higher surface pressures with lower changes in surface areas. In comparison with 
Pulmonary Surfactant and Drug Delivery 
 
92 
 
disconnected interfaces (Figure 33A), when they are connected (Figure 33B) the last compression 
isotherm is shifted to the right and start at higher pressures, indicating that there is more material 
in the interphase, and the plateau is more reduced. This is, less area compression is needed to 
overtake the plateau and reach higher pressure. This is advancing that more material could be 
present in the interface and likely enriched with DPPC. Although the pressure at the beginning of 
the last compression (end of 9th expansion) is clearly reduced in both cases, it is more evident 
when the bridge is absent, meaning that less material is in the interface and resulting in the shift 
of the isotherm (Figure 33C). Clearly, the loss of material is compensated with the surfactant 
reservoir coming from the donor, which is constantly adsorbing into the air-liquid interface and 
travelling along it. Focusing on the isotherm above the plateau in the presence of the bridge, it is 
possible to observe that it is even more right-shifted than the plateau in the first compression. 
This is another evidence that the material remained in the interface could be progressively 
enriching with DPPC. 
 
Figure 33: π-area isotherms comparing the first and last compression with pure DPPC. A) and B) representative 
π-area isotherms comparing the first and last compression with pure DPPC with the interfaces disconnected and 
connected, respectively. C) Minimal surface pressures after each expansion. Error bars correspond to standard 
deviation (n=3). 
After each experiment, the recipient interface was collected and fluorescence of 
TAC·NileBlue was measured at three different moments: before and after 10 compression-
expansion cycles and after the first compression. Figure 34A shows that fluorescence decays 
dramatically after the cycles, in accordance with the situation observed in the π-area isotherms. 
The same decrease can be observed after the first compression, confirming that the major 
exclusion is happening at that moment. Interestingly, when the cycles are performed with both 
interfaces connected, the fluorescence is considerably higher than the signal detected in the 
absence of the interfacial bridge (see Figure 34B). These results insinuate that, although TAC is 
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being excluded during the cycles, the presence of the bridge allows the continuous transference 
of material from the donor to the recipient trough. 
 
Figure 34: Fluorescence spectra. A) Measured in the recipient trough before and after the cycles and just after 
the first compression (different experiments) to highlight the exclusion of TAC after interfacial dynamics without 
the bridge. B) Comparison between cycling with or without the interfacial bridge. Relative fluorescence was 
calculated independently with respect to the maximum on each graph considering all replicates. Error bars 
correspond to standard deviation calculated in accordance to the measurement of relative fluorescence (n=3). 
3D structures: interfacial paths to scape 
Once knowing that interfacial dynamics promotes drug release from the interface, it wanted 
to be elucidated how this process takes place. Consequently, interfacial films derived from the 
previous experiments were transferred to mica and glass plates and imaged under atomic force 
and epifluorescence microscopes. Attending to the “squeeze-out” model 47, 65, three-dimensional 
structures associated to the interface were expected under compression conditions. Therefore, 
topographical analysis of the AFM images was performed and several representative are shown 
in Figure 35. Micro (1-2 µm) and nanodomains (70-120 nm) of liquid-condensed phases (Lc) 
can be observed at surface pressures just before reaching the plateau values. Some higher spots 
and worm-like structures of around 4 nm height are apparently formed on top of these nano and 
microdomains (arrows in Figure 35 A.1), though they are likely Le phases confined in Lc domains, 
as described in the literature 65. These structures, which are probably bilayers, confirmed the 
formation of 3D structures during compression of the interfacial film. At higher pressures on the 
plateau (see Figure 35 A.2 and A.3), these structures increase in height (up to 20 nm) and 
extension (up to 5 µm). The graphs below each image in Figure 35 represent the height of one 
section (white dashed lines) and give information about which kind of structures are forming. 
Knowing that a phospholipid monolayer measures around 1.5-2 nm and the difference in lipid 
phases is around 0.5-0.8 nm 186, 187, these results induce to think that the interface-associated 
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structures are monolayers and bilayers stacked on top of each other, reaching in some cases up 
to five bilayers. 
 
Figure 35: Topographical images taken with AFM before (A) and after (B) interfacial dynamics. 3D 
representation is located on top of the corresponding image. The graph on the left represents the π-area 
isotherm and indicates the pressure at which images were taken. Graphs below each image represents the 
height of one section (dashed lines). Arrows: A) white: worm-like structures (4 nm height); black: little spots (4 
nm height). B) white: crater-like structures with little spots inside (4 nm height); black: little spots (100nm width 
and 4-8 nm height). 
Surprisingly, Figure 35 B.1 shows that at low pressures after the cycles (≈8 mN/m), when 
liquid-expanded (Le) phases are expected to be bigger and more abundant, a more homogeneous 
and apparently more condensed phase is observed, instead. Little spots of up to 100 nm diameter 
and 4-8 nm in height can also be observed on top of those Lc phases (black arrows in Figure 35 
B.1). Bigger crater-like structures (1-1.5 µm diameter) with plenty of those little spots inside and 
around, are also observed with a huge erection (up to 220 nm height) placed on the side. At 
higher pressures below the plateau (≈30 mN/m; Figure 35 B.2), the structures showing several 
stacked monolayers and bilayers are observed again. However, they appear at lower pressures 
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than the same obtained before the interfacial dynamics. Interestingly, their diameter coincides with 
the crater-like structures measured at low pressures. These results likely suggest that once the 
3D structures are formed during the first compression, some could remain over the expansions 
acting as nucleation sites during the next successive cycles. 
When the interfacial films were observed under the epifluorescence microscope (see Figure 
36), highly intense spots were found in all assessed experimental conditions. They correspond to 
high concentration of fluorescent dyes NBD-PC and NileBlue which rearrange forming clusters 
during compression. After the cycles, the spots are smaller and the areas around completely dark. 
The intensity of fluorescence also decreases over compression and after the cycles. This suppose 
another evidence to confirm a possible lateral reorganization of the film during interfacial dynamics 
which leads to the accumulation of fluorescent dyes in specific locations before being excluded 
from the interface. 
 
Figure 36: Main structures formed in the surfactant film transferred from the recipient compartment. Images 
taken under an epifluorescence microscope from transferences of OE·NBD-PC + TAC·NileBlue films, before or 
after dynamic cycles with or without the interfacial bridge. White arrows indicate some examples of presumably 
excluded three-dimensional structures. The histogram was shortened to better differentiate the structures in 
the images. Red: TAC·NileBlue; Green: NBD-PC. Bar = 50 μm. 
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Surprisingly, comparing these images with those obtained using the AFM (see Figure 37), 
the fluorescent clusters coincide with the compression-driven three-dimensional structures, 
insinuating that TAC is being firstly accumulated those specific locations and then excluded from 
the interface through them, as if they were membranes tunnels connected to the interface. 
 
Figure 37: 3D structures seen in AFM corresponds to the brighter domains in epifluorescence. In 
epifluorescence, the histogram of each image was firstly shortened and then contrasted to better differentiate 
the fluorescent structures. Merge is shown (Red: TAC·NileBlue; Green: NBD-PC). Bar = 25 µm. 
Vehiculization in occupied interfaces 
All the previous experiments were performed in clean air-liquid interfaces. However, to 
approximate the experiments even more to what happens in the lung, vehiculization was analysed 
in previously occupied interfaces. Emulating the endogenous surfactant, the interface was firstly 
coated with limited amounts of NS (1 μL labelled with 1% mol BODIPY-PC at 50 mg/mL) to 
minimize the formation of surface-associated reservoirs in both donor and recipient troughs. After 
35 min to allow NS to coat both donor and recipient interfaces, a second addition of surfactant 
was applied (14μL at 50mg/mL). In this case, the sample was a combination of OE and 10% 
TAC (8% TAC + 2% TAC·NileBlue by mass), emulating the vehiculizing surfactant. The addition 
of drug/surfactant mixture was conducted following two different strategies: a) at static conditions 
CHAPTER II: A structural trip through a dynamic interface 
97 
 
to know whether surfactant can also travel and transport TAC through an already surfactant-
coated interface, and b) during compression-expansion cycles to evaluate if interfacial dynamics 
enhances the interfacial trip and the replenish of used surfactant. 
As illustrated in Figure 38, the initial addition of surfactant produced the typical jump in surface 
pressure up to 41-42 mN/m. However, after the first 5 minutes it plunges to 10-12 mN/m. This 
sharp reduction coincides with the beginning of the increase in the recipient before reaching the 
equilibrium at 10-12 mN/m. This suggests that surfactant that leaves the donor to travel to the 
recipient is not replenished due to the limited amounts of material applied to the donor. At the 
moment of adding the vehiculizing surfactant in static conditions (Figure 38A), the surface pressure 
surges again up to 41-42 mN/m in the donor trough and surfactant starts traveling interfacially 
until equilibrating at the same pressure in the recipient. Under dynamic conditions, the vehiculizing 
surfactant was added during the fifth expansion, but when surface pressure in the donor trough 
was still increasing (35 mN/m) due to the transmission of the compression of the recipient trough 
along the paper bridge. This addition of new material results in a notable increase in surface 
pressure at the donor trough, and a reduction in the previously-observed sharp fluctuations (Figure 
38B). At the same time, the minimum and maximum pressures of each cycle start to increase at 
the recipient trough. These results evidence that interfacial dynamics enhances not only 
depuration of interfacial films and enrichment of high-compressible phospholipids, but also the 
incorporation of new material coming from the donor reservoir, regardless the presence of 
surfactant occupying the interface. 
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Figure 38: Interfacial vehiculization of Tacrolimus into a surfactant-coated interface. Surface pressure has been 
monitored into donor and recipient troughs after covering the interface with NS·BODIPY-PC and posteriorly 
adding OE + TAC·NileBlue. The second surfactant addition was: (A) after 35 min in static conditions (black arrow), 
and (B) during fifth expansion (black arrow) leaving the experiment for five more cycles. 
Parallelly, images of each experiment were taken under the epifluorescence microscope. 
The idea was to observe how an exogenous-like surfactant behaves when it contacts with the 
endogenous-like surfactant which was previously applied, to confirm that surfactant transports 
TAC through a previously-coated interface and to see how TAC is distributed. Images in Figure 39 
illustrate how, regardless the strategy followed, the exogenous-like surfactant (red) reaches the 
recipient trough and mixes with the endogenous-like (green) at surface pressures below 
45mN/m. At higher pressures green fluorescence is not observed while red is clustered in brighter 
spots. This presumably results from the lateral exclusion of the drug from highly packed domains 
and the subsequent interfacial exclusion as happening in the experiments performed with clean 
interfaces. 
CHAPTER II: A structural trip through a dynamic interface 
99 
 
 
Figure 39: Main structures formed due to the diffusion of OE/TAC·NileBlue mixtures into a NS·BODIPY-PC 
coated interface. Epifluorescence images from the experiments adding surfactant suspensions before and  
during cycles. The histogram was shortened to better differentiate the structures in the images. Merge is shown 
(Red: TAC·NileBlue; Green: NBD-PC). Bar = 50 μm. 
A fluorescence overview 
In order to better interpret the former experiments, TAC·NileBlue fluorescence spectra of 
each experimental condition measured in the recipient trough, are represented together in Figure 
40. As clearly observed, the major fluorescence was obtained before performing interfacial 
dynamics. After the cycles, fluorescence decays considerable. However, this decrease is less 
noticeable when both interfaces are connected, indicating that although TAC is being excluded, 
new dye is coming from the donor reservoirs. Interestingly, even with the interfaces connected, 
fluorescence was slightly higher just after interfacial dynamics than 30 minutes later. 
 
Figure 40: Fluorescence spectra of TAC·NileBlue measured in the recipient trough after each experimental 
condition. Relative fluorescence was calculated independently with respect to the maximum on each graph 
considering all replicates. Error bars correspond to standard deviation calculated in accordance to the 
measurement of relative fluorescence (n=3). 
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DISCUSSION 
Few studies have addressed the mechanisms supporting the ability of PS to transport drugs 
through the air-liquid interface and, even lees, to know which are the insights involved in the 
release process. The previous chapter focused on the idea of vehiculizing hydrophobic drugs and 
how they could alter the interfacial functionality of different surfactant formulations. Nevertheless, 
as important as vehiculizing drugs is to release them in the desired locations. The squeeze-out 
model could give indirect evidences that the exclusion of drugs is happening through the interface-
associated 3D structures 47, as occurring with unsaturated phospholipids 65 or meconium 
components 188. However, no direct proofs are available showing the real mechanism behind the 
vehiculizing and exclusion process under dynamic conditions. The data presented here support 
the idea that the breathing-like compression and expansion dynamism, at which the respiratory 
surface is continuously subjected during the process of breathing, enhances the vehiculization of 
therapeutic passengers towards the alveoli and, once there, it promotes their exclusion via 
interfacial-associated 3D pathways. 
Exploring how a hydrophobic drug interacts with pulmonary surfactant and 
behaves interfacially 
Although the use of DPPC monolayers as a model of pulmonary surfactant cannot properly 
cover the entire insights of such a complex system, it could advance several essential cues to 
elucidate how TAC is interacting with it and behaves interfacially. The assays performed with 
monolayers of DPPC demonstrated that Tacrolimus is actually able to intercalate between DPPC 
molecules and somehow affects their lateral distribution under compression circumstances. The 
former can be interpreted as a positive sign since it is suggesting that pulmonary surfactant could 
contain certain amounts of TAC in its membranes to be vehiculized. The latter, on the other hand, 
could be interpreted as a negative effect since it is altering one of its most useful characteristics 
for the interfacial activity of pulmonary surfactant: the capacity of self-packing very tightly to form 
a solid-like phase able to displace water molecules from the interface reducing the surface tension. 
Nevertheless, deeply analysing the behaviour of DPPC monolayers in the presence of TAC upon 
compression, it emerges that TAC is excluded laterally first and then interfacially. The increase of 
lateral pressure undergoes a lateral rearrangement of the interfacial molecules in different clusters, 
attending basically to its size and capacity of packing. The presence of domains upon compression 
confirms that at certain lateral pressure, TAC cannot sterically resist and is laterally excluded to 
the fluid phase. The slight increase of fluorescence observed in the fluorescence images at the 
beginning of compression confirmed that, upon the lateral organization of the monolayer, the drug 
is firstly accumulated in the fluid phase. Then, at higher pressures, the drug is interfacially excluded 
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as the fluorescence of the fluid phase is considerable less upon this process. However, some 
signal is still detectable, indicating that not all the durg is excluded during the first compression. 
We additionally propose that during the lateral exclusion of TAC, the already-formed domain 
containing DPPC and NBD-PC around is disturbed, evidenced by a darker halo around the domains 
seen in Figure 25. In Figure 41 this exclusion model is proposed. This could be determinant for the 
interfacial rheology impairing its interfacial functions. 
 
Figure 41: Lateral and interfacial exclusion model. This model shows the compression-triggered lateral 
exclusion of TAC and NBD·PC from the highly packed domains of DPPC. At low surface pressures molecules at 
the interface have free movement and occupy more area (Fluid phase). Over compression, molecules start 
clustering and Tacrolimus (TAC), which cannot be compressed, is firstly excluded, disturbing the already-formed 
DPPC domain. At higher pressures, DPPC molecules pack tighter and NBD-PC is also excluded. Finally, the 
extremely high lateral pressure forces TAC and NBD-PC to leave the interface in a merely steric process. 
Having this in mind, we thought that if TAC is excluded from the interface over compression, 
the exclusion would be even higher making consecutive compression-expansion cycles. Effectively, 
although the major exclusion takes place during the first compression, the remaining TAC is 
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progressively excluded upon the cycles. This is a such depuration that leads DPPC to start packing 
at the same pressures than in the absence of the drug, forming the condense domains again. 
Nevertheless, in DPPC monolayers where no other elements leading this process are present (i.e. 
SP-B or SP-C), this exclusion is produced from fluid phases following an uncontrolled steric 
process. At this point, knowing that DPPC can hold TAC and the compression-expansion dynamics 
is promoting its exclusion, it becomes appropriate to introduce the rest of the elements in the 
system. Similarly, the experiments preformed using organic solutions of surfactant and following 
the Langmuir protocol to prepare interfacial monolayers confirmed the lateral clustering prior to 
the exclusion from the interface, as observed in the fluorescence images where the drug is 
localised in specific regions surrounded by highly packed domains. Additionally, the  broader 
transition plateau observed during the first compression at maximum amount of TAC evidences 
that the presence of the drug at pressures bellow 30 mN/m affects the phase transition of the 
lipid and triggers the depuration of the interfacial film during the first compression, likely disturbing 
the surroundings of condensed regions as observed in pure DPPC monolayers.  
In presence of organic extracts of surfactant, when unsaturated lipids and proteins are 
present also in the interface together with surfactant, the presence of vesicles-like full of TAC and 
NBD-PC out of the condense regions over the exclusion plateau above 34 mN/m is advancing 
that this exclusion is taking place at specific locations. Therefore, this process, still being a steric 
issue, seems to be accurately orchestrated. In fact, the characteristic plateau of surfactant 
supposes an indicative of the existence of structural transitions, where predominantly non-
compressible material folds down to reduce the surface tensions to values below 2mN/m. This 
structural transitions, which have been well studied, will be discussed in the next section.  
Dynamic vehiculization 
The experiments proposed in this section, where traditional Wilhelmy and Langmuir-Blodgett 
troughs are connected, allow to study surfactant films as never before. Since Dr. Clements 
proposed the Langmuir-Blodgett trough to study the structure of pulmonary surfactants, it has 
been one of the most used method. Traditionally, the way of forming monolayers and surfactant 
films has been by spreading an organic solution or aqueous suspension directly on the Langmuir-
Blodgett trough. Even applying the sample in organic solvents, which is widely thought that it 
ensures the formation of simple monolayers, exist the risk to unintentionally generate subjacent 
structures that could incur in erroneous interpretations. Levering the spreading properties of 
pulmonary surfactant, only the fraction absorbed into the interface of an independent trough and 
then spontaneously spread through an interfacial bridge to the Langmuir-Blodgett trough can be 
CHAPTER II: A structural trip through a dynamic interface 
103 
 
studied using this method. Apart from this, it is possible to reach the equilibrium surface pressure 
in this trough without reducing the area and study the native structures, avoiding the possible 
formation of them derived from compression-driven lateral segregation and allowing reaching 
minimal surface tensions close to physiological (2 mN/m) under compression. More importantly, 
once formed the surfactant film, the possibility of removing the bridge also allows to study this 
native-like film independently of any surfactant reservoir, which could also lead to erroneous 
interpretations. 
The assays carried out in the presence or in the absence of the interfacial bridge have 
demonstrated that the loss of interfacial material over interfacial dynamics in the recipient trough, 
and consequently in the donor due to the continuous spreading towards the recipient, activates 
the adsorption and interfacial trip of new material. Only in limiting conditions of surfactant, as 
there is not enough new surfactant accumulated in the subphase, the material that is being 
transferred from the donor to the recipient trough is not replaced. However, unrestricted amounts 
of surfactant added to the donor trough maintain the interface completely saturated, even when 
the material is traveling. This highlights the necessity of a continuous network of new and operative 
surfactant at the alveolar lining fluid in the lung to ensure a constant transference of material into 
the interface. When the recipient trough has no reservoirs with new surfactant (interfaces 
disconnected), all the material that was lost during the interfacial dynamics is not replaced, 
bringing to light that the excluded material is unable to readsorb, even after half an hour after the 
compression and expansion dynamics. However, in the presence of the bridge the material lost 
during the cycles is unequivocally replenished by new coming from the donor. This put on the 
table that the normal breathing cycles enhance the diffusion of PS towards the alveolar region 
and, consequently, the vehiculized passengers. It has been well established that the particular 
composition of PS, especially the presence of the hydrophobic surfactant proteins (SP-B and SP-
C), optimizes the interfacial behaviour of surfactant films during compression-expansion dynamics 
47 and facilitates the spreading of exogenous formulations. During compression, part of the 
material already at the interface folds down and is excluded from it to be recycled; during 
expansion, that released surfactant likely generates surface tension gradients. Leveraging such 
gradients, mostly towards the alveoli, and attending to the Marangoni effects 189, we speculate 
that exogenous surfactant and additional passengers that are properly associated could hook the 
endogenous surfactant and spread independently of fluid flows induced by the ciliated bronchial 
epithelia. Interfacial surfactant-associated phenomena could therefore allow reaching the alveolar 
region, with surfactant sharing the trip with additional elements, such as allergens, drugs or 
Pulmonary Surfactant and Drug Delivery 
 
104 
 
nanocarriers. However, further studies are required to evaluate the potential effect of fluid flows 
induced by the mucociliary escalator. 
The topographical and epifluorescence observations confirmed that the interfacial dynamics 
promotes the selective exclusion of material from the interface. As mentioned, this selectivity arises 
from a mere steric matter, where every molecule that cannot resist high lateral pressures is simply 
excluded from the interface. However, this loss of material far from taking place aleatory, is 
perfectly orchestrated and localized in specific locations at the interface. Transitions structures 
have been detected at pressures coinciding with the conspicuous plateau observed just above the 
equilibrium surface pressure (42-45 mN/m). This metastable 3D structures have been well 
studied, and it is widely accepted that they consist in an equilibrium coexistence between Le, Lc 
and collapsed phases 190. These collapsed phases, presumably formed under the coordination of 
the hydrophobic proteins SP-B and SP-C 191, are monolayers and bilayers stacked on top of each 
other 47, 192, 193. It is widely accepted that these multilayered 3D structures, through which part of 
the excluded material remain closely associated to the interface to ensure a proper amount of 
surfactant over the subsequent compressions, are enriched of unsaturated phospholipids 65. As 
observed in the topographical images, the 3D structures formed during the cycles seem to re-
extend again along the interface. However, little higher spots remain. Knowing that SP-B and SP-
C are critical to form, stabilise and re-expand these kind of structures, we suggest that these spots 
could be accumulations of these proteins. They cluster during compression and act as nucleation 
points from where unsaturated lipids and other molecules will be excluded from the interface 
during the subsequent compressions.  
Following the “squeeze-out” model, this work stablishes that, in a similar manner to 
unsaturated phospholipids, additional therapeutic passengers as TAC or corticoids are excluded 
to the subphase through these multilayered structures in the form of  three-dimensional structures. 
In fact, observing these structures under the epifluorescence microscope, we realised that both 
small and bigger 3D formations were completely full of TAC and NBD-PC, which labels the fluid 
phases where unsaturated phospholipids are expected to be. The TAC fluorescent spectra 
measurements revealed that fluorescence decayed after interfacial dynamics, concretely during 
compressions. Hence, the drug is unequivocally excluded from the interface. However, the 
excluded material is not able to readsorb, confirming in situ the existence of small aggregates of 
“used” surfactant unable to readsorb once excluded. These small aggregates has been reported 
to be enriched with unsaturated phospholipids and need to be removed from the alveolar lining 
fluid for recycling 65. 
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Attending to the fact that interfacial dynamics activates the adsorption and interfacial trip, 
one could anticipate that more TAC must be vehiculized and hence more should be detected over 
the cycles when both troughs are connected, especially after 30 minutes. Nonetheless, the 
fluorescence readings did not show the same. In an attempt to explain this, we speculate that 
over compression, non-compressible molecules form continuous pathways of fluid phases that 
converge into those 3D structures. Like interfacial rivers that merge in the subphase ocean. As 
shown in the literature 47 and in the topographical profiles of this work, the condensed micro and 
nanodomains coexist with a continuous network of Le phases, revealing the existence of these 
interfacial pathways. Once at the recipient trough, as TAC cannot intercalate between the already-
formed condensed phase, it could comfortably flow along the interfacial pathways to reach the 
3D structures, where it could diffuse to the subphase. So that it likely goes directly to the subphase 
and only the remaining in the interface can be detected. 
Regarding the material that remains at the interface, it seems to be refined. Judging by the 
shape of the isotherms after the cycles, which progressively reminds to DPPC, not only in the 
absence but also in the presence of the interfacial bridge, the material that stays at the interface 
tend to be DPPC. Although the initial amount of surfactant at the interface is not replaced 
completely (evidenced by the pressures at the end of the expansions), the high lateral pressures 
reached during compressions confirm that DPPC is not being excluded, or at least the majority. 
Additionally, several evidences suggest an enrichment of DPPC and simultaneous depuration of 
the material coming from donor reservoir: the reduction of necessary area to reach the maximum 
pressures, the concomitant shortening of the exclusion plateau and the fact that the pressures at 
the end of the expansions in the presence of the bridge do not change excessively. Conversely, 
in the absence of the bridge, the necessary area to reach the maximum pressures increases and 
the pressures at the end of the expansions decreased considerably. Therefore, this is another 
prove confirming that the interfacial material is being lost but DPPC still remains there. This makes 
sense from a biophysical and physiological point of view because DPPC is the main phospholipid 
able to resist the lateral pressures reached in the alveoli and then reducing the surface tension to 
values near 0 mN/m. It has been theorised in the literature that both a “selective adsorption” of 
DPPC 65, 194, 195, 196 or “selective exclusion” of non-DPPC lipids could be occurring. It has been 
proposed that this “selective adsorption” is due to the combined action of SP-B and SP-A 195, but 
the experiments performed in this thesis were made using the organic fraction of surfactant, where 
SP-A is absent. However, even though these experiments do not contradict the existence of a 
selective adsorption, we propose that the progressive enrichment of DPPC is due to a presumable 
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simpler continuous “selective exclusion”. The interfacial film is simultaneously depurated from 
uncompressible molecules constantly adsorbing with no other option than accumulate DPPC. The 
interesting and still unsolved question, common in both proposals, is how the amounts of DPPC 
in the interface are controlled. Is there a “selective exclusion” of DPPC orchestrated by surfactant 
proteins? Can cholesterol and SP-C be the ones involved in such a process? 
Therefore, this chapter clearly provides a robust understanding of the elementary processes 
involved in the interfacial pulmonary drug delivery. It demonstrates that interfacial dynamics 
favours even further the transference of material from the donor to the recipient trough and 
promotes the release of carried drugs from the interface towards the aqueous subphase, 
regardless a previous saturation of the interface with pulmonary surfactant. Nevertheless, to 
properly transfer the generated knowledge to clinics, it is necessary to perform further 
experiments, taking into account the native context that the desired therapy will encounter in the 
lungs. Therefore, the next chapter addresses the pulmonary surfactant-promoted drug delivery 
approach directly on lungs using in vivo systems. 
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INTRODUCTION 
The earlier in vitro biophysical studies demonstrated the potential use of pulmonary 
surfactant as a drug delivery system. This membrane-based lipid-protein material is able to pick 
up hydrophobic drugs, transport them long distances using air-liquid interfaces as a motorway 
and drop them off over the continuous interfacial compression and expansion dynamics. However, 
the relevance of these findings in intact lungs is poorly understood. Especially since the presence 
of mucus, immune system, pathogens, particles or the air and liquid flows produced during lung 
expansion and relaxation may impair this strategy drastically. Several in vivo studies have already 
demonstrated the synergistic effects of different surfactant/drug combinations such as antibiotics 
114, 115, 116, corticosteroids 120, 121, 122 or even nanoparticles containing siRNA 197. Nevertheless, none 
investigated how. Therefore, this chapter focuses on observing, describing and demonstrating the 
vehiculizing potential of pulmonary surfactant directly on lungs using in vivo systems. 
Consequently, it has been determined the distribution and efficacy of tacrolimus (also known as 
FK506 or TAC) as an airway-delivered drug model in a lipo-polysaccharide (LPS)-induced mouse 
model of acute lung injury. The idea was to detect synergistic anti-inflammatory effects when TAC 
is vehiculized in combination with exogenous pulmonary surfactant. 
Lipopolysaccharide, also known as endotoxin, is the invariant virulence factor present in the 
outer cell membrane of Gram-negative bacteria (i.e. Escherichia coli and Salmonella enterica) 198.  
It is one of the most potent activators of innate immune responses that triggers the activation of 
the inflammation process binding to Toll-like receptors (TLR), especially TLR-4 199, 200. Therefore, 
it has been extensively used to induce the inflammation process in lungs, generating in vivo models 
of ALI. LPS-induced ALI is mainly due to the disruption of the air-blood barrier integrity with the 
consequent extravasation of fluid, proteins and inflammatory cells (mostly neutrophils) into lungs 
201. The resulting protein leakage and ROS production completely destroy the alveolar balance, 
nourishing the overall inflammation 108. The treatment with anti-inflammatory drugs could reduce 
the extensive oedema and contribute to counteract the inflammatory process. 
In this regard, Tacrolimus (TAC) may be a good candidate. It is a hydrophobic 
immunomodulator firstly found in Streptomyces tsukubaensis 202, which has been widely used in 
transplantation of human lungs 203, 204 and other solid organs 205, 206 to prevent and treat allograft 
rejection. It has been extensively demonstrated that TAC supposes an effective treatment to lessen 
neutrophil activity and equilibrates the balance of pro-/anti-inflammatory cytokines, reducing the 
inflammation process 207.  Conjugated with FK binding proteins, TAC inhibits calcineurin, a 
phosphatase involved in intracellular signal transduction and blocks mitogen-activated protein 
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kinases (MAPKs) cascade and NF-κB. This inhibits pro-inflammatory cytokines production (i.e. IL-
1β and IL-6) and NOS, and triggers the expression of anti-inflammatory cytokines (i.e. IL-10, 
TGF-β and TNF-β) 208, 209, 210. 
The majority of the studies elucidating the effect of tacrolimus on inflammatory cells has 
been focused on T-cells and the adaptive immune responses. However, few evidences have 
demonstrated the effects of TAC on innate immune responses and the cells involved in this 
process. Some studies suggest that TAC firstly induces the activation of steady-state macrophages 
blocking the constitutively inhibition of TLRs by calcineurin 211, 212; then, it seems to trigger a 
process of tolerance to subsequent challenge with LPS, providing some protection against in vivo 
LPS-induced endotoxin shock 213, 214. With regard to the MAPKs pathway, TAC predominantly 
regulates cytokine production in activated macrophages through extracellular signal-regulated 
kinases (ERK) 212, 215, 216 , instead of c-Jun amino-terminal kinases (JNK) and p38 MAPKs, as 
occurring in T-cells. Additionally, TAC also induces apoptosis in inflammatory cells via caspases 3 
and 9, shifting to an anti-inflammatory environment 210. Moreover, apart from the anti-
inflammatory effects on T-cells 217, macrophages 218 and neutrophils, it has also been reported 
that TAC could act as an antifibrotic drug inhibiting the TGF-β-induced collagen synthesis in human 
lung fibroblastic cells 219, showing better prognosis in patients 220. 
THE IN VIVO MODEL 
In order to explore the feasibility of the new and non-invasive drug delivery strategy 
proposed in this thesis, in vivo models have been used. As aforementioned, TAC has anti-
inflammatory effects, then LPS-induced mice models for inflammation have been proposed to 
assess the potential synergistic effects of delivering the drug in combination with pulmonary 
surfactant and whether it enhances the distribution through the respiratory surface. Accordingly, 
in anesthetized Swiss Webster mice (8-10 week old and 30-40g weight), different solutions were 
sequentially intranasally instilled (see Figure 42): a) PBS (30 µL) at 0 and 1 h for control; b) PBS 
(30 µL) and LPS (5 mg/Kg; Lipopolysaccharides from Escherichia coli O111:B4 from Sigma-
Aldrich) at 0 and 1 h, respectively for a pro-inflammatory group; c) own-purified porcine surfactant 
(50 µL; 10 mg/mL) and LPS (5 mg/Kg) at 0 and 1 h, respectively to test non-specific surfactant 
effects; d) TAC·NileBlue (50 µL; 15 µg) and LPS (5 mg/Kg) at 0 and 1 h, respectively to examine 
specific anti-inflammatory effects derived from the drug; and e) 50 µL of a combination of 
Surfactant (10mg/mL) + TAC·NileBlue (15µg; 1.5% wt), respectively to evaluate the synergistic 
anti-inflammatory effects. TAC was fluorescently labelled with NileBlue to track the distribution. 
Five hours after the last instillation, the mice were anesthetized and exsanguinated through the 
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heart. Then, 1 mL of ice-cold PBS was intra-tracheally instilled and withdrawn the bronchoalveolar 
lavage (BAL). Additionally, the same experiments were carried out in mice whose macrophages 
were previously depleted by clodronate. An aqueous suspension (60 µL; 7 mg/mL) of liposome-
encapsulated clodronate (Clodrosome® from Encapsula NanoSciences LLC, USA) was 
intranasally instilled (15 mg/kg) to anesthetised mice. After two days, mice were treated as 
described in Figure 42. 
 
Figure 42: Experiment protocol. A) Experimental conditions. B) Example of intranasal instillation. C) Performed 
experiments using bronchoalveolar lavages to evaluate the anti-inflammatory effects and distribution of TAC 
trough the respiratory surface. 
In a 9 µL BAL aliquot, Turk’s solution (1:10 v/v) was added, in which acetic acid (1-2%) 
destroys RBCs and gentian violet stains nuclei making cells visible for counting on the 
haemocytometer (counted in four different squares of 0.04 mm2; four aliquots per mouse BAL). 
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Then, the remaining BAL was centrifuged to separate cells (15 min; 4 °C; 800 G).  The 
supernatant was used to determine the protein content by the bicinchoninic acid (BCA) assay to 
determine the existence of edema, while the pellet to directly observe the presence of red blood 
cells (RBC), as a sign of pulmonary edema, and determine which BAL cells uptake TAC. For the 
latter, the pellet was resuspended in PBS (1 mL) and conveniently diluted before centrifuging in 
a Cytospin™ 4 Cytocentrifuge (5 min; 4 °C; 2000 rpm) to deposit the appropriate number of 
cells in a glass slide. Then, the cells were fixed with methanol (99%) to observe them under the 
fluorescence microscope (Olympus IX81) in search of those that uptake TAC. Additionally, the 
cells were stained with Giemsa solution (30 min) to morphologically distinguish the different cell 
populations in BAL. The samples stained with Giemsa could not be observed to evaluate the TAC 
uptake, as this colourant is also visible with the same filter used for TAC·NileBlue, complicating 
the correct interpretation of the images by inducing false positives (see Figure 43). Therefore, it is 
necessary to prepare the samples separately to distinguish the cell populations (Giemsa staining) 
and observe the TAC·NileBlue fluorescence (no stain, just the fluorescently labelled TAC). 
 
Figure 43: Giemsa emits fluorescence in a similar wavelength to TAC·NileBlue. The images correspond to 
bronchoalveolar cells observed under bright-field and fluorescence microscopy. After the cytospin, cells were 
directly fixed with methanol (- GIEMSA) or stained with Giemsa (+ GIEMSA). LPS samples (up) correspond to a 
negative control for TAC·NileBlue, while T·S + LPS (down) represents the positive control. When the cells were 
stained with Giemsa, a fluorescence signal can be observed even in the absence of TAC·NileBlue (LPS, + GIEMSA, 
TAC channel). If they are not stained (LPS, - GIEMSA, TAC channel) a fluorescence signal is not observed. In the 
case of T·S + LPS samples, TAC·NileBlue fluorescence is detected inside some cells (T·S + LPS, - GIEMSA, TAC 
channel), as expected. When they were stained with Giemsa (T·S + LPS, + GIEMSA, TAC channel) all the cells emit 
fluorescence. Although the fluorescence pattern is slightly different in those cells where TAC is expected to be 
(macrophages; white arrows), Giemsa stain complicates the correct interpretation of images. 
RESULTS 
To determine the anti-inflammatory effects of TAC and explore the possible synergistic 
effects of delivering it in combination with pulmonary surfactant, very basic inflammatory indicators 
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were evaluated from bronchoalveolar lavages (BALs) of five different groups of mice as described 
below. First, the amount of white blood cells (WBC) was calculated among the several conditions 
to determine the anti-inflammatory effect of the different formulations. Then, the presence of 
pulmonary oedema was analysed by observing the presence of red blood cells (RBC) and 
measuring the total protein content in the BAL. Finally, the TAC uptake in BAL cells were observed 
under the epifluorescence microscope. 
Surfactant/TAC combinations produce synergistic effects 
Figure 44 shows that the amount of WBC increased significantly in LPS-induced inflammation 
(LPS; 1.71±0.29 million/mL; mean ± SD, n=4) in comparison with the control group (PBS; 
0.21±0.04 million/mL; mean ± SD, n=4). The treatment with only tacrolimus (T + LPS) or 
surfactant (S + LPS) did not counteract the LPS-mediated WBC increase (2.20±0.52 and 
2.29±0.21 million/mL, respectively; mean ± SD, n=4). Nevertheless, when mice were pre-
treated with tacrolimus vehiculized with pulmonary surfactant (T·S + LPS), the amount of WBC 
was greatly reduced (0.64±0.12 million/mL; mean ± SD, n=4), revealing that surfactant/TAC 
combinations have, somehow, synergistic effects. 
 
Figure 44: White blood cells (WBC) count in bronchoalveolar lavages (BALs). Mean of four mice is represented 
for each condition (four different squares of 0.04 mm2 were observed; four aliquots per mouse BAL were 
counted). Error bars represent the standard deviation. (*) p<0.01 (One Way ANOVA, Holm-Sidak method). 
The pellets obtained after centrifuging the BALs were merely observed (see Figure 45). The 
group of mice treated with LPS (LPS) clearly showed a reddish colour, evidencing the presence 
of red blood cells in the alveolar spaces, which usually suggests pulmonary edema. Those groups 
pre-treated with only TAC (T + LPS) or pulmonary surfactant (S + LPS) also presented a red 
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colour. However, when mice were pre-treated with TAC in combination with pulmonary surfactant 
(T·S + LPS), the pellet presented a yellowish colour like the control group (PBS), indicating that 
the extravasation of blood components to alveolar spaces was reduced. 
 
Figure 45: Pellets obtained after centrifuging BALs. Representative images of n=4 for each condition. 
Something similar occurred when the total protein content was measured in the different 
bronchoalveolar lavages. As shown in Figure 46, the protein content in the LPS and T + LPS groups 
(0.70±0.38 and 0.86±0.55 mg/mL, respectively; mean ± SD, n=4) is significantly higher than 
the control (0.22±0.04 mg/mL; mean ± SD, n=4), evidencing that the LPS-promoted edema is 
not counteracted by the administered doses of tacrolimus. In the case of those mice pre-treated 
only with surfactant (S + LPS), the total protein content seems to be reduced (0.37±0.16 
mg/mL; mean ± SD, n=4), although the differences with respect to LPS group are not statistically 
significant. On the other hand, the treatment with surfactant/tacrolimus combination clearly shows 
a great reduction of BAL proteins (0.20±0.04 mg/mL; mean ± SD, n=4). 
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Figure 46: Total protein content in bronchoalveolar lavages (BALs). Mean of n=4 is represented for each 
condition. Error bars represent the standard deviation. (*) p<0.05 and (**) p<0.01 (Mann-Whitney Rank Sum 
Test). 
TAC uptake as a proof of surfactant-mediated interfacial distribution 
Before determining if TAC is captured by cells, it is convenient to characterise which types 
of cells are present in the different experimental conditions. Consequently, the pool of cells isolated 
from BALs was conveniently stained with Giemsa, which is a colouring agent widely used to 
morphologically differentiate blood and BAL cells 221. Figure 47 shows the different cell populations 
that coexist in the airways in the absence and the presence of LPS-induced inflammation (A), and 
the proportion of macrophages in each experimental situations (B). In steady-state conditions 
(PBS group), the pool of bronchoalveolar cells is mainly composed by macrophages (97±2%; 
mean ± SD; n=3), ideally AMϕ, characterised by big rounded deep blueish nuclei and granulized 
cytoplasm. However, in LPS-induced inflammatory conditions, the percentage of macrophages 
decreases (LPS: 9±4%; T + LPS: 5±3%; S + LPS: 13±9%;  T·S + LPS: 9±6%; mean ± SD; 
n=3) as a consequence of a massive extravasation of blood elements, especially neutrophils 
(polymorphonucleated with deep blue-violet segmented-like nuclei) and erythrocytes (salmon-
pink) (see Figure 47A). Although neutrophils remain in all LPS-induced conditions, erythrocytes 
decrease considerably in mice pre-treated with TAC in combination with surfactant (also showed 
in Figure 45). 
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Figure 47: Cell populations in BALs. A) Representative images of each experimental condition are shown. Cells 
were stained with Giemsa to morphologically distinguish every cell population. Black arrows: macrophages; blue 
arrows: neutrophils; red arrows: erythrocytes. Bar = 100 µm. B) Percentage of macrophages with respect to 
total amount of WBC in BAL. The left axis represents the number of WBC expressed in million cells in 1 mL of 
BAL (stripped bars); the right axis corresponds to the percentage of macrophages with respect to WBC in BAL 
(smooth bars). Each percentage of macrophages was obtained by observing the slides stained with Giemsa. Bars 
represent mean of six different images per mice (n=3). Error bars represent the standard deviation. 
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In order to elucidate if TAC is internalised by alveolar cells and if pulmonary surfactant 
enhances this process, the WBC obtained from bronchoalveolar lavages were observed under the 
fluorescence microscope. Figure 48 shows representative images of the groups of mice pre-treated 
with TAC in the absence and in the presence of surfactant (A), the percentage of cells that uptake 
TAC (B) and the fluorescence intensity inside the cells as an indicator of internalised TAC (C). In 
the absence of TAC·NileBlue fluorescence was not detected, thus the images are not shown. The 
images clearly show that in combination with surfactant, TAC is internalised by many more cells. 
However, not every types of cells uptake TAC. Indeed, analysing their morphology, likely 
macrophages are the ones that internalise the drug. The percentage of cells that uptake TAC 
when it is vehiculized by pulmonary surfactant (7.9±5.1%; mean ± SD; n=3) is higher than 
delivering it alone (1.4±1.1%; mean ± SD; n=3) and coincides with the percentage of 
macrophages. These results suggest that macrophages internalise TAC and pulmonary surfactant 
seems to facilitate the process, either by improving the distribution along the respiratory surface 
or by leveraging the process of surfactant clearance. These evidences are coherent considering 
that alveolar macrophages are specialised in clearing surfactant from the alveolar spaces 15, 28, 62. 
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Figure 48: TAC uptake by BAL cells. A) Cells from BAL of LPS-induced inflammation mice models pre-treated 
with TAC·NileBlue in the presence and the absence of pulmonary surfactant. The bigger images correspond to a 
merge between bright field and fluorescence microscopy. Clearly, not all kinds of cells show TAC·NileBlue 
fluorescence. The amplifications correspond to an example of those cells that internalize TAC. Attending 
uniquely to the morphology, those cells seem to be macrophages. Notice that in the presence of surfactant the 
intensity of fluorescence is higher. The histogram of each image was equally adjusted to better differentiate the 
presence of TAC inside the cells. Bar = 100 µm. B) Percentage of cells that internalise TAC. In combination with 
pulmonary surfactant the amount of cells that uptake TAC is considerably higher. Each percentage was obtained 
by observing the slides previously fixed with MetOH and applying the same threshold to avoid background. The 
rest of conditions (PBS, LPS and S+LPS) are not shown, as no fluorescence was detected. Bars represent mean of 
six different images per mouse (n=3). Error bars represent the standard deviation. C) Fluorescence intensity of 
TAC·NileBlue inside cells. In combination with surfactant, cells internalize a higher amount of TAC. Fluorescence 
intensity was measured by ImageJ (Fiji). Three different regions of cytoplasm were aleatory measured from each 
cell on six images per mouse (n=3). T·S + LPS: 60 cells; T+LPS: 8 cells, as less cells uptake TAC. Mean is 
represented. Error bars correspond to standard deviation. 
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To further confirm the selective uptake of TAC inside macrophages and whether the anti-
inflammatory effect of TAC is accomplished through them, mice were intranasally instilled with 
liposome-encapsulated clodronate (15 mg/kg), whose apoptotic effect on macrophages was 
widely demonstrated in the literature 93, 222, 223. Two days after clodronate administration, mice 
were treated with different solutions following the same protocol for the previous experiments 
(see Figure 42). Figure 49 A shows the presence of neutrophils and cellular debris in the control 
group (Clod + PBS), a sign of pro-inflammatory and apoptotic processes. The evaluations of total 
protein content and WBC counting in BAL (see Figure 49 B and C, respectively) also showed a 
considerable increase of the inflammation process in the control group (Clod + PBS) and no signs 
of anti-inflammatory effects were observed in the TAC-treated groups. These results reveal that 
the depletion and loss of activity of AMϕ induced by clodronate disrupt the pro-/anti-inflammatory 
balance. Therefore, the effect of Clodronate, whose pathway of action is completely different to 
LPS or TAC, hides the anti-inflammatory effects of TAC in LPS-induced lung injury mice. Thus, 
these models cannot be considered to evaluate the anti-inflammatory effects of TAC alone or in 
combination with pulmonary surfactant. 
 
Figure 49: Effect of clodronate (Clod) in bronchoalveolar fluid. A) Representative images of control groups (PBS) 
in the presence and in the absence of clodronate. Cells were stained with Giemsa to morphologically distinguish 
every cell population. Black arrows: macrophages; blue arrows: neutrophils; red arrows: erythrocytes. Bar = 
100 µm. B) Total protein content in BAL (stripped bars: without clodronate; smooth bars: with clodronate). Mean 
of n mice (indicated under the bars) is represented for each condition (stripped bars: without clodronate; 
smooth bars: with clodronate). Error bars represent the standard deviation. (*) p<0.001 (Mann-Whitney Rank 
Sum Test). C) WBC count in BAL (stripped bars: without clodronate; smooth bars: with clodronate). Mean of n 
mice (indicated under the bars) is represented for each condition (four different squares of 0.04 mm2 were 
observed; four aliquots per mouse BAL were counted). Error bars represent the standard deviation. (*) p<0.001 
(Mann-Whitney Rank Sum Test). 
Nevertheless, the clodronate effect on AMϕ is useful to further confirm that the cells which 
internalise TAC are macrophages. Figure 50A shows two representative images of LPS-induced 
mice pre-treated with surfactant/TAC combinations which have previously treated with clodronate 
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or not. The internalization of TAC in BAL cells is considerably reduced in those mice treated with 
clodronate, even in the remining macrophages (likely in an apoptotic state). This evidences that 
TAC, especially vehiculized in pulmonary surfactant, is actually internalised by no other type of cell 
than macrophages. 
 
Figure 50: Effect of clodronate on bronchoalveolar cells. Cells from BAL of LPS-induced inflammation mice 
models pre-treated with TAC·NileBlue in the presence and the absence of pulmonary surfactant. The bigger 
images correspond to a merge between bright field and fluorescence microscopy. In the absence of clodronate, 
the TAC·NileBlue fluorescence is clearly detected inside macrophages, while in its presence the fluorescence 
signal is drastically reduced. Fluorescence associated to cellular debris is also observed, indicating that the 
integrity of BAL cells (likely macrophages) is compromised by clodronate. They cannot resist the centrifugation 
forces during the cytospin and finally burst (white arrows). The amplifications correspond to an example of those 
cells that internalize TAC. The histogram of each image was equally adjusted to better differentiate the presence 
of TAC inside the cells. Bar = 100 µm. 
DISCUSSION 
The previous chapters have demonstrated and characterised for the first time the 
possibilities of using pulmonary surfactant as a drug delivery system. It has been confirmed in 
vitro its ability to travel long distances along air-liquid interfaces and share this interfacial trip with 
additional passengers. Moreover, it has been observed how the breathing-like compression and 
expansion dynamics enhances the release process after travelling interfacially. However, these 
promising results obtained by using biophysical in vitro models  did not simulate the entire barriers 
that the lungs have developed to prevent the entrance of foreign entities (i.e. branched structure, 
mucus, immune system or the air and liquid flows). Therefore, the inevitable following step was 
to prove the concept of surfactant-driven drug vehiculization in vivo. This was possible using a 
mouse model of LPS-induced ALI that allows to evaluate 1) the feasibility of this new and non-
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invasive pulmonary drug delivery system, 2) the anti-inflammatory properties of tacrolimus 
vehiculized by pulmonary surfactant, 3) what occurs after reaching alveolar spaces and 4) which 
cells are involved in this novel strategy. 
Certainly, TAC was selectively internalised in macrophages and the amount was considerably 
higher in combination with pulmonary surfactant. At the same time, the oedema as well as the 
amounts of WBC were visible reduced in LPS-challenged mice pre-treated with surfactant/drug 
combinations. These results induce to think that: 1) surfactant is an effective and efficient 
interfacial system, able to reach the alveolar spaces and transport TAC from the nose, 2) it 
enhances the availability and internalisation of TAC by alveolar macrophages and 3) it promotes 
the resulting anti-inflammatory effect possibly via macrophages. 
It is extensively known that alveolar macrophages are specialised in removing and 
catabolising the ‘used’ surfactant excluded during the process of breathing in the form of small 
aggregates 62. The previous in vitro results showed that TAC is excluded from the interface in 
small vesicles of surfactant components unable to readsorb, fruit of breathing-like interfacial 
compression/expansion dynamics. Therefore, the presence of higher amount of TAC in 
macrophages of surfactant-treated mice clearly induces to think that TAC is being excluded in 
small surfactant aggregates during breathing, and then phagocyted by alveolar macrophages. 
Thus, surfactant could be an efficient drug delivery system to carry hydrophobic compounds 
toward specific cells, allowing to reach precise lung targets such as alveolar macrophages. 
Additionally, apart from the aforementioned properties, attending to the spreading capabilities of 
pulmonary surfactant, it could enhance the distribution of the drug along the respiratory surface 
and reach more easily regions in the lungs that are difficult for the drug alone. Thus, more amount 
of drug can be available in the alveolar spaces to take its effect or cross the air-blood barrier. 
Additionally, the treatment with only surfactant tends to prevent the protein leakage but not 
the WBC extravasation, likely as a consequence of the surface active properties of pulmonary 
surfactant. In fact, apart from the capillary blood pressure and plasma and tissue fluid osmotic 
pressure, surface tension is the other force that maintains the alveolar lining fluid stable impeding 
the ultra-filtration of fluid coming from the blood stream 224. When the thin air-blood barrier is 
compromised by an inflammation process (i.e. LPS-induced), the permeability increases and blood 
components enter into the alveolar space. Some of the plasma components and inflammation-
derived enzymes impair the function of pulmonary surfactant either by competing for the interface 
(i.e. albumin) or degrading its components (i.e. phospholipase A2) 108. This inactivation, together 
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with the dilution of the pulmonary surfactant, leads to an increase in surface tension destabilising 
those forces with the consequent increase of oedema. The reduction of total proteins in BAL from 
mice pre-treated with exogenous surfactant seen in this study may be due to the fact that this 
surfactant counteracts the inhibition of the endogenous surfactant, either by replacing the used 
and inhibited one or inducing production of new and more active surfactant. This was the principle 
to start using the surfactant replacement therapy (SRT) in adults with ALI. Unfortunately, this 
therapeutic strategy was not as effective as expected in clinical trials 225. Nevertheless, the 
surfactants used in those clinical trials had limitations in composition and functionality (Exosurf® 
225, Survanta® 226 or Venticute® 111). The way of delivery (aerosolization with ancient nebulizers) 
and dosage (only once or several intermittent) also limited the studies. The presence of surfactant 
inhibitors during inflammation, mainly phospholipase A2, finally inhibits the exogenous surfactant 
as well, especially when only one dose is administered and surfactants are not biophysically 
competent. Therefore, a multidose treatment with proper combinations of exogenous surfactants 
and anti-inflammatory drugs could empower the effect of SRT in ALI. Moreover, a continuous 
exposure to the treatment in nebulised formulations using the last generation of electrical 
nebulizers (i.e. based on Vibrating Mesh Technology) instead of intermittent intratracheal 
administration, could enhance even more the therapeutic efficacy and could contribute to reduce 
the high dosage needed in adults. This is possible not only leveraging the therapeutic properties 
of surfactant per se, but also using it to improve the distribution and targeting of the anti-
inflammatory drug along the respiratory surface. 
In summary, the use of pulmonary surfactant as a vehicle helps to distribute the drug along 
the respiratory surface from the upper airways to alveoli, enhancing at the same time the process 
of internalization into alveolar cells, apparently macrophages, and augmenting the anti-
inflammatory response of the drug in LPS-challenged mice. All these evidences open novel 
avenues to treat diseases where the drug distribution and alveolar macrophages play a key role 
such as tuberculosis and pulmonary fibrosis or symptoms derived from acute lung injury. 
Nevertheless, this new drug delivery approach must be accompanied with the development and 
production of new surfactants that can improve the essential properties: good adsorption and 
spreading along the air-liquid interface and the ability to vehiculize and resist to inhibition. Such 
qualitative optimization, along to the creation of synthetic surfactants to control composition and 
produce larger quantities, of material a reasonable cost are the tendency nowadays. 
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One of the challenges in the last few years has been to design and develop new strategies 
in drug delivery. These strategies should allow overcoming different biological barriers in a non-
invasive way and targeting specific locations in the body. In this sense, the respiratory system is 
proposed as a preferred pathway, principally because of the typical features of the respiratory 
surface (thin, large and highly vascularised) and the presence of pulmonary surfactant. The latter, 
historically considered a barrier and essential for the process of breathing, can be used as a carrier 
and to assist in solving different limitations of the current approaches, such as poor solubility of 
hydrophobic drugs, or to reach places in the lungs that are barely accessible, such as the alveolar 
spaces. Surfactant is an amphipathic material able to adsorb and localise into the interface 
between the layer of water covering the whole respiratory surface and the breathing air and, once 
there, to spread very efficiently over it. Considering these spreading capabilities, the main objective 
of this Thesis has been to assess the potential of pulmonary surfactant to deliver different drugs 
through the airways as a basis of a novel and non-invasive strategy, the ‘interfacial therapy’. In 
order to explore this concept, an special in vitro setup was designed, mimicking somehow the 
connection through an air-liquid interface of upper and distal compartments of the airways. It 
consist in two different aqueous troughs connected by an interfacial bridge, so that pulmonary 
surfactant can travel from one to another only through the interface. Using this apparently simple 
device, it has been demonstrated in vitro for the first time the vehiculizing potential of pulmonary 
surfactant and that the compression and expansion breathing-like dynamics enhances the release 
of drugs from the air-liquid interface. Once the potential of this novel interfacial drug delivery 
strategy was demonstrated, it was also confirmed in vivo. Surprisingly, not only pulmonary 
surfactant was able to transport a drug like tacrolimus from the upper airways to distal alveoli, but 
also to deliver it towards the alveolar macrophages, which internalised the drug leading a 
synergistic anti-inflammatory effect in combination with pulmonary surfactant. The combination of 
biophysical and in vivo models has undoubtedly confirmed the extraordinary possibilities of 
pulmonary surfactant as a drug delivery system. 
Nowadays, pulmonary surfactant is being widely used to treat the Respiratory Distress 
Syndrome in prematurely born babies. Unfortunately, clinical trials have failed to support the 
delivery of surfactant alone as a protective therapy in adult Acute Lung Injury (ALI) 108, 225. 
However, those clinical trials presented important constraints with respect to the election of 
therapeutic surfactants, which had compositional and functional limitations, including uncertainties 
with respect to the delivery route and the specific dosages. The results of the present Thesis 
suggest that the combined administration of anti-inflammatory drugs and exogenous surfactants 
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might constitute an important adjuvant effect. This consideration is strongly supported by the 
unique interfacial properties of pulmonary surfactant, the advantages of using the respiratory 
surface as a way for drug delivery and the ongoing improvements in surfactant delivery strategies. 
The drug delivery capacities of pulmonary surfactant could go beyond the patients with surfactant 
problems, such as those of RDS. The challenge is to target local (lung) and peripheral pathologies, 
improving the delivery, targeting and effectiveness of different drugs through their association to 
pulmonary surfactant. 
The results of this Thesis also illustrate the utility of biophysical models to analyse the 
elementary processes involved in the interfacial pulmonary drug distribution, which could be 
tailored to study the behaviour of any particular drug or therapeutic agent (peptides, proteins, 
RNA, DNA, etc.). They are a potent tool to design and optimize new surfactant vehiculization 
strategies prior to in vivo experimentation, which may reduce the use of animal models. Important 
aspects that can be optimised in a case-by-case basis include: 1) the incorporation of additional 
passengers (i.e. drugs, antibodies, siRNA or nanocarriers), 2) the maximal surfactant/passenger 
proportion that still maintain the integrity of surfactant biophysical properties, 3) the efficacy of 
the cmbined interfacial trip and 4) the interfacial behaviour under breathing-like dynamic 
conditions.  
However, to properly transfer this knowledge to clinics, it is mandatory to consider the 
physiological context that the desired therapy will encounter in the lung. First of all, it is necessary 
to take into account that the distribution of clinical surfactant/drug combinations will not encounter 
an empty and clean interface at the lungs.  In fact, the pulmonary interface will be already occupied 
by different materials, such as endogenous surfactant, or it would be extended on top of a thick 
layer of mucus layer at the upper airways. In this regard, additional experiments have been already 
carried out to analyse how the spreading of surfactant-loaded drugs over the interface is 
modulated in a surfactant-occupied interface. The obtained results suggest that the exogenous 
surfactant is able to interact with the endogenous surfactant film one without disturbing drug 
spreading. However, these promising data still need to be complemented with further experiments 
testing surfaces already coated with viscous complex solutions such as mucus 227. On the other 
hand, the flow of fluid and particles into the upper airways is much influenced by the active 
participation of the mucociliary escalator, in charge of clearing accidentally inspired and potentially 
noxious entities 228. Nevertheless, still under that particular environment, the fate of molecules 
firmly associated to the interfacial film likely differs from those molecules that move independently.  
It has been widely demonstrated that exogenous surfactant can efficiently distribute over the 
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airways and reach alveoli when delivered as an endotracheal bolus 229, 230, 231. Thus, interfacial 
flows follow different movements than those involving the subphase. In this line, a preliminary 
study carried out at the laboratory of Prof. Jahar Bhattacharya´s laboratory in Columbia University, 
New York, has shown that surfactant is able to distribute TAC over mouse lungs reaching the 
alveolar spaces. In these preliminary experiments, a surfactant/TAC mixture was intranasally 
applied into the upper airways. Then, the isolated perfused lungs were observed under a confocal 
microscope showing that TAC·NileBlue fluorescence could be detected in alveoli. This result, 
pending of additional required controls, demonstrates the surfactant-assisted interfacial 
distribution over the respiratory surface. It also points out the idea that surfactant can flow against 
the mucociliary current and is competent to transport additional passengers with it. 
The interfacial diffusion of surfactant/drug formulations could also be affected by the 
presence in the subphase and in the interface of different substances released as a consequence 
of lung injury, such as serum, or inflammatory mediators. These compounds may affect lung 
surfactant, impairing both its interfacial adsorption and spreading. In this regard, the combination 
of an efficient therapeutic surfactant with proper drugs could simultaneously address the intended 
pharmacological action and the restoration of the surfactant biophysical function. In this sense, 
different specific formulations of therapeutic surfactants could be designed for drug delivery 
depending on the clinical conditions of target lungs (properly aerated lungs or injured lungs 
requiring restoration of  pulmonary surfactant inhibition). Additionally, the proper choice of the 
amounts of surfactant to be delivered along with the optimal surfactant/drug proportions could 
be crucial to allow for their rapid and efficient distribution over the interface. Up to now, the 
efficient clinical doses of the majority of approved therapeutic surfactants for SRT are above 50 
mg/Kg at concentrations higher than 25 mg/mL 42, 108. Nevertheless, the results obtained in the 
present Thesis have proven that lower doses of interfacial material can efficiently deliver drugs 
(15 mg/Kg at 10 mg/mL). This positive outcome is not surprising and the amount of surfactant 
could be further reduced in future experiments. Theoretically, only 3 mg/Kg is the estimated dose 
of exogenous surfactants to saturate the respiratory surface (1 m2/Kg body weight) and reduce 
the surface tension to values below 2 mN/m2. 
A last important consideration is related to how pulmonary surfactant is usually delivered in 
exogenous therapies. Restoration of impaired surfactant function is frequently performed by 
applying clinical surfactants endotracheally in patients that are intubated as a consequence of their 
respiratory problems. Those patients could have better expectations if treated with a proper 
combination of surfactant and drugs. However, the strategies of non-invasive administration are 
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critical to obtain better and faster results. In this line, to be efficient, those approaches must still 
preserve the dynamic properties that make surfactant an extraordinary pharmacological agent with 
huge therapeutic delivery potential. The possibility of using aerosolised surfactant would face both 
the current problems related to patients intubation and reduce the hospitalization costs. Although 
several experiments performed in animals to date had no clear success, promising results were 
obtained by studying the vehiculizing capacity of lyophilised and nebulised clinical and synthetic 
surfactants. The used of a last generation of electrical nebulizers and current clinical and synthetic 
surfactants, is opening unprecedented avenues in surfactant and respiratory drug delivery. 
The complexity of the pulmonary surfactant system and the necessity to maintain its 
biophysical properties intact, makes mandatory to evaluate each surfactant/drug combination in 
a case by case basis. In this thesis, only three different drugs have been studied to demonstrate 
and stablish the basis of the surfactant-driven interfacail vehiculization (beclomethasone 
dipropionate, budenoside and tacrolimus). Nevertheless, other molecules have also been tested, 
demonstrating that hydrophobicity is the most important aspect to consider. For instance, 
structural and functional preliminary experiments combining surfactant with amiodarone, a highly 
hydrophobic drug (AlogP = 6.94) used to treat and prevent irregular heartbeats that produces 
lung toxicity, showed that comparable amounts to those used for corticoids and tacrolimus (10% 
by mass) disturbed the interfacial properties of pulmonary surfactant drastically. Hydrophilic 
molecules, on the other hand, such as the antituberculotic drug isoniazid (AlogP = -0.77), have 
also been tested showing no interaction with pulmonary surfactant. This highlights the importance 
to design optimal carriers able to interact with pulmonary surfactant while encapsulating 
hydrophilic drugs and preventing the possible deleterious effects of hydrophobic therapeutics. 
The potential use of liposomes in combination with pulmonary surfactant, which could be a 
promising way for delivering hydrophilic drugs, has also been explored. Unfortunately, the 
experiments carried out in our laboratory have shown disappointing results. These membrane-
based nanocarriers resulted inefficient to transport hydrophilic molecules once contacting with 
surfactant components. Liposomes, as they are composed by phospholipids, easily fuse with 
surfactant membranes releasing the cargo even before it can be vehiculized. Some alternatives 
could be explored such as the use of polymeric micro or nanocarriers or viral capsids. The feasibility 
of functionalising the surface of these carriers with surfactant components, click-chemistry-based 
elements or antibodies could increase the range of possibilities, with a great potential to enhance 
the surfactant-promoted vehiculization of nanocarriers. 
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The increasing use of proteins as therapeutic agents, such as antibodies for the treatment 
of cancer, antibiotic peptides or antigen vaccination through the airways, highlights the importance 
of exploring the vehiculization of proteins in combination with pulmonary surfactant as well. In this 
sense, preliminary studies with SP-D have already demonstrated that pulmonary surfactant is able 
to interact and interfacially transport this hydrophilic surfactant protein. SP-D cannot travel on its 
own, thus confirming the importance of pulmonary surfactant to allow its distribution over the air-
liquid interface. These data bring to light the possibilities of delivering proteins associated to 
pulmonary surfactant. 
To summarize, the promising data exposed in this Thesis highlights the importance of 
continuing exploring the vehiculization capabilities of pulmonary surfactant, developing new and 
non-invasive ways for administering it, and elucidating how it can improve the distribution, target 
and effectiveness of any therapeutic agent (i.e. specific drugs, anti-bodies, siRNA or even cells) 
for both local diseases (i.e. fibrosis, ARDS or lung cancer) or peripheral delivery. Knowing that 
alveolar macrophages are the main actors in surfactant clearance, it will be also essential to have 
them into account and study their role on this delivery strategy and on local pathologies (how 
they migrate and get involved, how they could change or define new markers related with 
communication with epithelium and with other alveolar-resident/non-resident cells or how they 
can be modulated with therapeutic purposes, etc.). Additionally, it will be also of great potential 
to seek sophisticated in vitro models to: 1) design and optimize new synthetic surfactants specially 
tailored for vehiculization, 2) explore the diffusion through the air-blood barrier to treat peripheral 
diseases, and 3) investigate on how other barriers (i.e. mucus, air and liquid flows or immune 
system) could affect this novel strategy. 
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Pulmonary surfactant, a lipid-protein complex with high surface activity, is an efficient vehicle 
for transporting drugs over the whole respiratory surface. In this Thesis, an in vitro model of the 
respiratory air-liquid interface has been designed and optimised to study the potential use of 
pulmonary surfactant as a drug delivery system and the implications of compression-expansion 
breathing-like dynamics in surfactant-assisted drug diffusion through the air-liquid interface. 
Combining this biophysical model with an in vivo murine model, it has been demonstrated that: 
1. Clinical and synthetic surfactants can incorporate hydrophobic drugs, such as corticosteroids 
or the anti-inflammatory tacrolimus, without affecting its functional properties. 
2. Different surfactant formulations can transport drugs facilitating their distribution through in 
vitro and in vivo air-liquid interfaces. 
3. Compression-expansion breathing-like dynamics enhance the interfacial trip and drug 
release from the air-liquid interface. 
4. Pulmonary surfactant facilitates the distribution of drugs such as the hydrophobic anti-
inflammatory tacrolimus in vivo, as observed in a murine model of endotoxin-caused lung 
injury. 
5. Pulmonary surfactant facilitates vehiculization of drugs like tacrolimus toward the distal 
airways. Once at the alveolar spaces, the drug is liberated and taken by macrophages. 
6. Surfactant/drug combinations have synergistic effects when administered in vivo, as 
observed in a model of administration of surfactant/tacrolimus in mice. 
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